End-To-End Clinical Trial Matching with Large Language Models

In oncology, clinical trials serve two purposes: they offer potential therapeutic benefits to cancer patients across all disease stages, ranging from early intervention to experimental treatments for those with limited or exhausted standard care options^1,2. They are also crucial to advance scientific research, as new treatments can only be approved through rigorous clinical testing. However, the practical realization of clinical trial enrollments still remains far from satisfactory, from both patient and clinician perspectives. For clinicians, identifying suitable trials is often time-consuming³ and complex due to patient-related factors such as performance status or comorbidities, logistical challenges like regional trial availability, systemic issues including lack of access to genomic testing, and the difficulty clinicians might face in locating available trials, all of which contribute to low enrollment rates of only 2-3% of potential trial candidates⁴.

Overall, there are three primary reasons for this:

First, the sheer volume of data generated during oncologic treatments, including hospital stay records, as well as genomic and imaging data, often accumulate, drastically increasing the burden on physicians^5–7. These data are typically fragmented and unstructured⁸, comprising free text, tabular records, and more⁸. Secondly, the complexity and volume of clinical trials tailored to oncology further complicate the process. There are approximately 500,000 studies registered on ClinicalTrials.gov, out of which 105,732 are dedicated to patients with cancer as of May 2024. Like patient records, trial information often includes unstructured information, such as plain text eligibility criteria and requires complex logical combinations of disease conditions, histologic subtypes, molecular markers and comorbidities⁹. Thirdly, from a patient's perspective, due to the evolution of the disease and the need to avoid patient attrition from deteriorating clinical conditions, it is crucial that the time to inclusion and initiation of treatment in clinical trials is minimized to the shortest possible duration.

From a practical perspective, addressing these challenges requires clinicians to follow a two-step process: first, they must screen for potential trial candidates based on key patient criteria such as tumor type, stage, mutations and availability within the patient’s area of residence; then, they need to perform detailed one-on-one matches of all the patient’s information with each candidate trial’s eligibility criteria.

So far, computational support tools designed to simplify this process have focused on only one of these steps at a time. For the first step, systems have primarily used embedding techniques, where patient and trial text data are converted into a numerical representation space and matched based on approximate mathematical similarity^10,11. For the second step, most tools focus on converting unstructured text from patient records and trial information into a tabular-like format. For instance, Criteria2Query uses machine learning and rule-based methods to parse inclusion and exclusion criteria into a structured format accessible via database queries¹².

Only recently, with advances in generative AI, particularly Large Language Models (LLMs) like GPT-4¹³, extracting and structuring information from medical documents has been drastically simplified¹⁴. The potential of LLMs has also been explored for matching patients to clinical trials based on comparing eligibility criteria to patient records¹⁵. For instance, den Hamer et al.¹⁶ demonstrated that LLMs can accurately provide eligibility labels such as ‘yes’, ‘no’, or ‘unknown’ when given both trial information and patient data as input at the same time. In oncology, Wong et al.¹⁷ extended this idea to account for complex logical conditions using a hierarchical matching procedure, showing that GPT-4 can excel at this task even without additional training. Fine-tuning LLMs on annotated trial data has markedly improved their performance even further. This approach has facilitated the development of a local, privacy-preserving model that closely rivals the capabilities of proprietary, large cloud-based LLMs¹⁸. Recently, the same research team created OncoLLM¹⁹, a new model that significantly reduces the performance gap with the current leading model, GPT-4.

Nevertheless, the aforementioned projects have several limitations:

First, they tend to focus on either step one or step two of the process, rather than integrating both. Additionally, for step one, discrete criteria such as recruitment status or intervention type take on only discrete values (e.g. sex, location or recruitment status), which would more effectively be managed through direct selection or filtering rather than embedding-based approaches that rely on inexact similarity matches. Second, all current LLM-based methods heavily rely on narrowly engineered prompts, which can be lengthy and cumbersome (Wong et al.¹⁷ report prompts of up to four pages). Third, due to the free-text nature in which eligibility criteria and patient information are processed by the model²⁰, there is no guarantee that the responses will adhere strictly to the required criteria structure.

We herein present a fully end-to-end pipeline for clinical trial matching which we designed to overcome the aforementioned limitations. Our approach is based on two principles: using LLMs as central reasoning agents²¹ capable of taking actions and programmatically enforcing trial eligibility criteria as structured programming objects rather than plain free text, thereby ensuring the model consistently outputs validly annotated information²².

Our contributions are the following:

1. 1.

   To the best of our knowledge, we present the first truly end-to-end pipeline for clinical trial matching, starting with searching relevant trial candidates for a given patient from all cancer trials available world wide and ending with fully-annotated trial eligibility criteria for a relevant set of trials.

2. 2.

   We provide an extensive and profound benchmarking, encompassing 51 oncology cases and matching over 1,580 single trial criteria that have been annotated by five human experts. We provide evidence that our pipeline excels in both, reliably filtering relevant trials from tens of thousands and providing highly accurate one-on-one eligibility matches with criterion-level feedback and explanations for users.

3. 3.

   We demonstrate that LLMs can outperform medical doctors in clinical trial matching. Our findings reveal that nearly 40% of the initially contradictory answers between GPT-4o and physicians were accepted as valid responses upon refining the human baseline with criterion-level AI feedback, resulting in an overall criterion-level accuracy of 92.7% for our pipeline.

4. 4.

   By enforcing trial eligibility criteria as structured programming objects rather than relying on them as free-text inputs, we guarantee that the LLM always outputs precisely and validly annotated information.

In this work, we describe and validate a fully end-to-end approach for leveraging LLMs for clinical trial matching using oncology cases as an example. Overall, we demonstrate how GPT-4o can first effectively screen potential trial candidates from a collection of over one hundred thousand clinical trials registered on clinicaltrials.gov and secondly match selected candidates on a criterion-by-criterion basis to patient records.

This has several real-world advantages: From a clinical perspective, physicians must filter out over 99.9% of irrelevant trials due to differing tumor types, disease stages, or distant locations. Additionally, they must consider what type of trials they are specifically looking for: Should they target a particular molecular alteration? Are they seeking trials for treatment-naive patients, or for those refractory to other therapies? Consequently, physicians are often forced to rely on ad hoc searches rather than structured methods to find suitable clinical trials. Given the inherent capabilities of state-of-the-art LLMs, we show that the process of filtering relevant trials by keyword-based search can be automated using GPT-4o, which can itself write queries for a No-SQL database, guided without or with human supervision, such as “Please find a Phase 1 trial for the patient in Germany” or “Could you please find a clinical trial for the patient’s KRAS mutation (or all of the patient’s mutations)?”

Our approach leverages the robust capabilities of GPT-4o in generating valid computer code, allowing programmatic access to trial databases with only optional human guidance. For instance, GPT-4o can request trials in specific locations or target particular mutations, or combinations of both if given as instruction from medical professionals. This makes our system highly scalable and flexible, extending its applicability beyond pre-selecting trials from a single center, as demonstrated by Gupta et al.¹⁹

Moreover, we are convinced of the inherent reasoning capabilities of LLMs²¹, particularly looking toward future advancements, allowing them to handle complex logic internally. In contrast, the approach by Wong et al.¹⁷ explicitly enforces LLMs to rewrite eligibility logic into structured Disjunctive Normal Form (DNF), imposing constraints on the model by limiting the combination of categories such as disease state, histology, and biomarkers through logical conditions (and, or, all, any, not etc.). This method also alters the original trial criteria, complicating human evaluation. Our approach ensures that the model’s output can be mapped back to the original criteria on a one-by-one basis, with each criterion accompanied by a detailed chain of reasoning explaining the model’s decision. This allows medical doctors to fact-check each decision of the model, ensuring explainability and trust. By understanding why the model reaches a particular conclusion and identifying potential errors we can better understand capabilities and limitations of current LLMs in managing EHR data.

Additionally, we demonstrate that our system’s performance can match and under certain conditions even surpass that of human experts in criterion decision tasks. Although not directly comparable due to different trials and patient data (Gupta et al. utilize real-world de-identified EHR cases) and potential variations in how trial criteria are processed, our overall pipeline achieves an accuracy of 92.7% and 97.4% when excluding N/A samples. This exceeds the results others have previously achieved with GPT-4, reporting accuracies of 68% and 72%, respectively¹⁹.

Moreover, our program-rather-than-prompt strategy ensures that responses consistently adhere to the required format, reducing the burden of finding optimal, often specific and narrow prompts. We therefore can guarantee that regardless of the length or complexity of the criteria, we receive validly annotated and unaltered criteria back from the LLM, which is not the case if criteria are handled as plain, free text.

Also, this approach allows the broad transferability of our system to other medical domains, with minimal need for adjustments, such as only the need for addressing domain-specific edge cases.

Nevertheless, our study has several limitations: In real-world scenarios, under current regulatory restrictions, GPT-4o is not a suitable candidate due to its cloud-based nature, which necessitates transferring sensitive patient data to proprietary servers. Thus, we consider GPT-4o as a best-in-class model suitable for proof-of-concept purposes. We anticipate that local model solutions will catch up in performance in the near future, making them more suitable for clinical application. Additionally, real-world patient data will be required to fully validate applicability of our system, incorporating longer and even more diverse patient documents. For instance, laboratory values may be nested in spreadsheets, and imaging data might be separate, with all relevant patient information distributed across various documents. Moreover, we aim to evaluate the model’s ability to accurately rank and prioritize the most relevant trials, enabling doctors to quickly identify the best options for their patients. Although our system currently provides scores based on the number and ratio of fulfilled eligibility criteria, we have not yet established a sophisticated measure for quantitative evaluation. We plan to develop and refine this using real-world data in the near future.

Despite these challenges, our work demonstrates that an LLM can autonomously narrow down relevant trials from thousands to a manageable handful and accurately match these trials criterion by criterion. To our knowledge, our study is the closest in mirroring the real-world scenario of how medical doctors interact with clinical trial databases like clinicaltrials.gov. This evidence suggests significant potential for our approach, particularly as we show, for the first time, that AI feedback can enhance the performance of medical specialists in identifying suitable clinical trials for their patients.

We thank OpenAI for supporting our work through a researcher access grant.

1. Bouzalmate-Hajjaj, A., Massó Guijarro, P., Khan, K. S., Bueno-Cavanillas, A. & Cano-Ibáñez, N. Benefits of Participation in Clinical Trials: An Umbrella Review. Int. J. Environ. Res. Public Health 19, (2022).

2. Unger, J. M., Cook, E., Tai, E. & Bleyer, A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ Book 35, 185–198 (2016).

3. Penberthy, L. T., Dahman, B. A., Petkov, V. I. & DeShazo, J. P. Effort required in eligibility screening for clinical trials. J. Oncol. Pract. 8, 365–370 (2012).

4. Unger, J. M., Vaidya, R., Hershman, D. L., Minasian, L. M. & Fleury, M. E. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. J. Natl. Cancer Inst. 111, 245–255 (2019).

5. Oxentenko, A. S., West, C. P., Popkave, C., Weinberger, S. E. & Kolars, J. C. Time spent on clinical documentation: a survey of internal medicine residents and program directors. Arch. Intern. Med. 170, 377–380 (2010).

6. Rule, A., Bedrick, S., Chiang, M. F. & Hribar, M. R. Length and Redundancy of Outpatient Progress Notes Across a Decade at an Academic Medical Center. JAMA Netw Open 4, e2115334 (2021).

7. Moy, A. J. et al. Measurement of clinical documentation burden among physicians and nurses using electronic health records: a scoping review. J. Am. Med. Inform. Assoc. 28, 998–1008 (2021).

8. Kong, H.-J. Managing Unstructured Big Data in Healthcare System. Healthc. Inform. Res. 25, 1–2 (2019).

9. Bradley, J., Kelly, K. & Stinchcombe, T. E. The Ever-Increasing Number of Trial Eligibility Criteria: Time to Bend the Curve. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer vol. 12 1459–1460 (2017).

10. Zhang, X., Xiao, C., Glass, L. M. & Sun, J. DeepEnroll: Patient-Trial Matching with Deep Embedding and Entailment Prediction. arXiv [cs.AI] (2020).

11. Gao, J., Xiao, C., Glass, L. M. & Sun, J. COMPOSE: Cross-Modal Pseudo-Siamese Network for Patient Trial Matching. in Proceedings of the 26th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining 803–812 (Association for Computing Machinery, New York, NY, USA, 2020).

12. Yuan, C. et al. Criteria2Query: a natural language interface to clinical databases for cohort definition. J. Am. Med. Inform. Assoc. 26, 294–305 (2019).

13. OpenAI et al. GPT-4 Technical Report. arXiv [cs.CL] (2023).

14. Wiest, I. C. et al. From Text to Tables: A Local Privacy Preserving Large Language Model for Structured Information Retrieval from Medical Documents. medRxiv 2023.12.07.23299648 (2023) doi:10.1101/2023.12.07.23299648.

15. Jin, Q. et al. Matching Patients to Clinical Trials with Large Language Models. ArXiv (2024).

16. den Hamer, D. M., Schoor, P., Polak, T. B. & Kapitan, D. Improving Patient Pre-screening for Clinical Trials: Assisting Physicians with Large Language Models. arXiv [cs.LG] (2023).

17. Wong, C. et al. Scaling Clinical Trial Matching Using Large Language Models: A Case Study in Oncology. in Proceedings of the 8th Machine Learning for Healthcare Conference (eds. Deshpande, K. et al.) vol. 219 846–862 (PMLR, 11–12 Aug 2023).

18. Nievas, M., Basu, A., Wang, Y. & Singh, H. Distilling large language models for matching patients to clinical trials. J. Am. Med. Inform. Assoc. (2024) doi:10.1093/jamia/ocae073.

19. Gupta, S. K. et al. PRISM: Patient Records Interpretation for Semantic Clinical Trial Matching using Large Language Models. arXiv [cs.CL] (2024).

20. Wornow, M. et al. Zero-Shot Clinical Trial Patient Matching with LLMs. arXiv [cs.CL] (2024).

21. Truhn, D., Reis-Filho, J. S. & Kather, J. N. Large language models should be used as scientific reasoning engines, not knowledge databases. Nat. Med. 29, 2983–2984 (2023).

22. Singhvi, A. et al. DSPy Assertions: Computational Constraints for Self-Refining Language Model Pipelines. arXiv [cs.CL] (2023).

23. Cattell, R. Scalable SQL and NoSQL data stores. SIGMOD Rec. 39, 12–27 (2011).

24. Chroma. https://www.trychroma.com/.

25. Benary, M. et al. Leveraging Large Language Models for Decision Support in Personalized Oncology. JAMA Netw Open 6, e2343689 (2023).

26. Lammert, J. et al. Expert-guided large language models for clinical decision support in precision oncology. (2024) doi:10.2139/ssrn.4855985.

27. Welcome to pydantic - pydantic. https://docs.pydantic.dev/latest/.

28. Introducing Rerank 3: A new foundation model for efficient enterprise search & retrieval. Cohere https://cohere.com/blog/rerank-3.

29. Sasazawa, Y., Yokote, K., Imaichi, O. & Sogawa, Y. Text Retrieval with Multi-Stage Re-Ranking Models. arXiv [cs.IR] (2023).

Supplementary Table 1. Model Instructions for Trial Search.

Supplementary Table 2. Unstructured eligibility criteria for NCT02227251: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Supplementary Table 3. LLM-structured eligibility criteria for NCT02227251: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Supplementary Table 4. Fully evaluated clinical trial eligibility criteria for Patient 1.1.1.

Supplementary Figure 1. Web-based user interface for assessing trial eligibility criteria on a per patient basis.

Supplementary Table 5. Clinical Case EHRs.

Supplementary Table 5. Clinical Cases EHRs.
Note: Color highlighting is for illustration only, and not provided to the model.

===== Patient 1.1 =====

Patient Information
Name: Emily Johnson
Born: October 15, 1967
Address: 5678 Maple Avenue, Springfield, IL, United States

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV and unresectable lung adenocarcinoma; adenocarcinoma histology, PD-L1
Initial Detection: March 10, 2023, following persistent chest pain and dyspnea
Biopsy Date: March 25, 2023
Molecular Profile: KRAS p.G13D, TP53 p.A276G, PTPRS R238*, ZFHX3 p.F2994L, CDH1 p.D433N

Therapy Overview
Initial Treatment: None
Comorbidities: Well-managed and not contraindicating any treatment

Comorbidities

Hyperlipidemia

Osteoarthritis

Gastroesophageal Reflux Disease (GERD)

Iron deficiency anemia

Medication

Simvastatin 40mg once daily (0-0-1)

Esomeprazole 20mg once daily (1-0-0)

Ferrous sulfate one tablet daily (1-0-0)

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

January 15, 2020: Routine annual physical examination revealed elevated blood pressure. Diagnosed with hypertension and prescribed Lisinopril 10 mg daily.

March 20, 2020: Complaints of frequent heartburn and acid reflux. Diagnosed with GERD and prescribed Esomeprazole 20 mg daily.

February 5, 2021: Follow-up for hypertension showed well-controlled blood pressure. Lisinopril dosage maintained.

May 25, 2021: Complained of knee pain and stiffness. Diagnosed with osteoarthritis. Recommended over-the-counter NSAIDs for pain management.

April 15, 2022: Routine check-up revealed elevated blood glucose levels. Diagnosed with Type 2 Diabetes Mellitus and prescribed Metformin 500 mg twice daily.

August 10, 2022: Routine cholesterol check indicated high cholesterol levels. Diagnosed with hyperlipidemia and prescribed Simvastatin 20 mg daily.

November 15, 2022: Follow-up for diabetes and hyperlipidemia. Dosages adjusted: Metformin increased to 1000 mg twice daily, Simvastatin increased to 40 mg daily.

February 20, 2023: Complained of shortness of breath and chronic cough. Diagnosed with mild COPD. Prescribed Salbutamol inhaler.

July 10, 2023: Routine follow-up showed stable condition with controlled comorbidities. Blood pressure, blood sugar, and cholesterol levels within target ranges.

March 10, 2024: Experienced persistent chest pain and shortness of breath. Chest X-ray and CT scan revealed a mass in the right lung.

March 15, 2024: CT Angiography, Pulmonary Arteries: Tumor Size: Approximately 4.7 cm in diameter. Bronchial Obstruction: Partial obstruction of the right main bronchus leading to atelectasis of the right upper lobe. Urgent suspicion of a tumor-atelectasis complex in the right upper lobe of the lung. Mucus present in the lower lobe bronchi on the right. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum.

March 25, 2024: CT-guided lung biopsy: Diagnosed with non-small cell lung cancer (NSCLC), adenocarcinoma. Molecular diagnostics: KRAS p.G13D, TP53 p.A276G, PTPRS R238*, ZFHX3 p.F2994L, CDH1 p.D433N.

April 20, 2024: Detailed assessment of health status. ECOG performance status 1.

April 21, 2024: Routine Lab:

Leukocytes 4,200/mcL, Lymphocytes 600/mm³, Absolute Neutrophil Count (ANC) 1,200/mcL

Platelets 150 × 10³/uL

Hemoglobin 9.0 g/dL

Total Bilirubin 1.3 mg/dL

Aspartate Aminotransferase (AST) 50 U/L

Alanine Aminotransferase (ALT) 60 U/L

Alkaline Phosphatase 200 U/L

Creatinine 1.4 mg/dL

L-thyroxin (T4) 8.5 µg/dL

Thyroid Stimulating Hormone (TSH) 2.0 µIU/mL

Blood Glucose 90 mg/dL

Cholesterol 180 mg/dL

HCG within normal range.

April 22, 2024: Molecular tumor board: Recommendation for trial inclusion.

===== Patient 1.1.1 =====

Patient Information
Name: Emily Johnson
Born: October 15, 1967
Address: 5678 Maple Avenue, Springfield, IL, United States

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV and unresectable lung adenocarcinoma; adenocarcinoma histology, PD-L1
Initial Detection: March 10, 2023, following persistent chest pain and dyspnea
Biopsy Date: March 25, 2023
Molecular Profile: KRAS p.G13D, TP53 p.A276G, PTPRS R238*, ZFHX3 p.F2994L, CDH1 p.D433N

Therapy Overview
Initial Treatment: None
Comorbidities: Well-managed and not contraindicating any treatment

Comorbidities

Hyperlipidemia

Osteoarthritis

Gastroesophageal Reflux Disease (GERD)

Iron deficiency anemia

Medication

Simvastatin 40mg once daily (0-0-1)

Esomeprazole 20mg once daily (1-0-0)

Ferrous sulfate one tablet daily (1-0-0)

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

January 15, 2020: Routine annual physical examination revealed elevated blood pressure. Diagnosed with hypertension and prescribed Lisinopril 10 mg daily.

March 20, 2020: Complaints of frequent heartburn and acid reflux. Diagnosed with GERD and prescribed Esomeprazole 20 mg daily.

February 5, 2021: Follow-up for hypertension showed well-controlled blood pressure. Lisinopril dosage maintained.

May 25, 2021: Complained of knee pain and stiffness. Diagnosed with osteoarthritis. Recommended over-the-counter NSAIDs for pain management.

April 15, 2022: Routine check-up revealed elevated blood glucose levels. Diagnosed with Type 2 Diabetes Mellitus and prescribed Metformin 500 mg twice daily.

August 10, 2022: Routine cholesterol check indicated high cholesterol levels. Diagnosed with hyperlipidemia and prescribed Simvastatin 20 mg daily.

November 15, 2022: Follow-up for diabetes and hyperlipidemia. Dosages adjusted: Metformin increased to 1000 mg twice daily, Simvastatin increased to 40 mg daily.

February 20, 2023: Complained of shortness of breath and chronic cough. Diagnosed with mild COPD. Prescribed Salbutamol inhaler.

July 10, 2023: Routine follow-up showed stable condition with controlled comorbidities. Blood pressure, blood sugar, and cholesterol levels within target ranges.

March 10, 2024: Experienced persistent chest pain and shortness of breath. Chest X-ray and CT scan revealed a mass in the right lung.

March 15, 2024: CT Angiography, Pulmonary Arteries: Tumor Size: Approximately 4.7 cm in diameter. Bronchial Obstruction: Partial obstruction of the right main bronchus leading to atelectasis of the right upper lobe. Urgent suspicion of a tumor-atelectasis complex in the right upper lobe of the lung. Mucus present in the lower lobe bronchi on the right. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum.

March 25, 2024: CT-guided lung biopsy: Diagnosed with non-small cell lung cancer (NSCLC), adenocarcinoma. Molecular diagnostics: KRAS p.G13D, TP53 p.A276G, PTPRS R238*, ZFHX3 p.F2994L, CDH1 p.D433N.

April 20, 2024: Detailed assessment of health status. ECOG performance status 1.

April 21, 2024: Routine Lab:

Leukocytes 2,700/mcL, Lymphocytes 438/mm³, Absolute Neutrophil Count (ANC) 1,200/mcL

Platelets 150 × 10³/uL

Hemoglobin 9.0 g/dL

Total Bilirubin 1.3 mg/dL

Aspartate Aminotransferase (AST) 50 U/L

Alanine Aminotransferase (ALT) 60 U/L

Alkaline Phosphatase 200 U/L

Creatinine 1.4 mg/dL

L-thyroxin (T4) 8.5 µg/dL

Thyroid Stimulating Hormone (TSH) 2.0 µIU/mL

Blood Glucose 90 mg/dL

Cholesterol 180 mg/dL

HCG +++++

April 22, 2024: Molecular tumor board: Recommendation for trial inclusion.

===== Patient 1.1.2 =====

Patient Information
Name: Emily Johnson
Born: October 15, 1967
Address: 5678 Maple Avenue, Springfield, IL, United States

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV and unresectable lung adenocarcinoma, M+ (BRAIN); adenocarcinoma histology,

Initial Detection: March 10, 2023, following persistent chest pain and dyspnea
Biopsy Date: March 25, 2023
Molecular Profile: KRAS p.G13D, TP53 p.A276G, PTPRS R238*, ZFHX3 p.F2994L, CDH1 p.D433N

Therapy Overview
Initial Treatment: None
Comorbidities: Well-managed and not contraindicating any treatment

Comorbidities

Hyperlipidemia

Osteoarthritis

Gastroesophageal Reflux Disease (GERD)

Iron deficiency anemia

HIV

Medication

Simvastatin 40mg once daily (0-0-1)

Esomeprazole 20mg once daily (1-0-0)

Ferrous sulfate one tablet daily (1-0-0)

Biktarvy (1-0-0)

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

January 15, 2020: Routine annual physical examination revealed elevated blood pressure. Diagnosed with hypertension and prescribed Lisinopril 10 mg daily.

March 20, 2020: Complaints of frequent heartburn and acid reflux. Diagnosed with GERD and prescribed Esomeprazole 20 mg daily.

February 5, 2021: Follow-up for hypertension showed well-controlled blood pressure. Lisinopril dosage maintained.

May 25, 2021: Complained of knee pain and stiffness. Diagnosed with osteoarthritis. Recommended over-the-counter NSAIDs for pain management.

April 15, 2022: Routine check-up revealed elevated blood glucose levels. Diagnosed with Type 2 Diabetes Mellitus and prescribed Metformin 500 mg twice daily.

August 10, 2022: Routine cholesterol check indicated high cholesterol levels. Diagnosed with hyperlipidemia and prescribed Simvastatin 20 mg daily.

November 15, 2022: Follow-up for diabetes and hyperlipidemia. Dosages adjusted: Metformin increased to 1000 mg twice daily, Simvastatin increased to 40 mg daily.

February 20, 2023: Complained of shortness of breath and chronic cough. Diagnosed with mild COPD. Prescribed Salbutamol inhaler.

July 10, 2023: Routine follow-up showed stable condition with controlled comorbidities. Blood pressure, blood sugar, and cholesterol levels within target ranges.

March 10, 2024: Experienced persistent chest pain and shortness of breath. Chest X-ray and CT scan revealed a mass in the right lung.

March 15, 2024: CT Angiography, Pulmonary Arteries: Tumor Size: Approximately 4.7 cm in diameter. Bronchial Obstruction: Partial obstruction of the right main bronchus leading to atelectasis of the right upper lobe. Urgent suspicion of a tumor-atelectasis complex in the right upper lobe of the lung. Mucus present in the lower lobe bronchi on the right. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum.

March 20, 2024: MRI-Brain: three metastatic lesions consistent with primary lung cancer. Lesions are located in the left frontal lobe, left parietal lobe, and left occipital lobe, measuring 1.2 cm, 1.5 cm, and 1.8 cm in diameter, respectively.
Surrounding vasogenic edema is noted, causing mild mass effect on adjacent
brain structures. No evidence of hemorrhage or hydrocephalus observed.

March 25, 2024: CT-guided lung biopsy: Diagnosed with non-small cell lung cancer (NSCLC), adenocarcinoma. Molecular diagnostics: KRAS p.G13D, TP53 p.A276G, PTPRS R238*, ZFHX3 p.F2994L, CDH1 p.D433N.

April 20, 2024: Detailed assessment of health status. ECOG performance status 1.

April 21, 2024: Routine Lab:

Leukocytes 4,200/mcL, Lymphocytes 600/mm³, Absolute Neutrophil Count (ANC) 1,200/mcL

Platelets 150 × 10³/uL

Hemoglobin 9.0 g/dL

Total Bilirubin 1.3 mg/dL

Aspartate Aminotransferase (AST) 50 U/L

Alanine Aminotransferase (ALT) 60 U/L

Alkaline Phosphatase 200 U/L

Creatinine 1.4 mg/dL

L-thyroxin (T4) 8.5 µg/dL

Thyroid Stimulating Hormone (TSH) 2.0 µIU/mL

Blood Glucose 90 mg/dL

Cholesterol 180 mg/dL

HCG within normal range.

SO2 (room air) 87%

April 22, 2024: Molecular tumor board: Recommendation for trial inclusion.

===== Patient 2.1 =====

Patient Information
Name: Sarah Mitchell
Born: June 12, 1998
Address: 8765 Pine Street, Springfield, IL

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV urachal adenocarcinoma; m+ (LYM, PULMONARY)
Initial Detection: January 18, 2024, following persistent hematuria and abdominal discomfort
Biopsy Date: January 28, 2024
Molecular Profile: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6)

Therapy Overview
Chemotherapy: Began February 1 - April 22, 2024 (Cisplatin + 5-FU)

Comorbidities

Seasonal Allergies

Medication

Cetirizine 10mg as needed

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

January 18, 2024: Presented with hematuria and abdominal discomfort. Abdominal ultrasound revealed a mass in the bladder dome.

January 22, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, measuring approximately 3.0 cm in diameter. Evidence of local invasion into surrounding structures + several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, measuring 1.5 cm.

Chest CT scan: Multiple metastatic lesions are present in both lungs. The largest metastasis is located peripherally in the left lung and measures approximately 3.1 cm in diameter. Other smaller metastatic nodules scattered throughout both lung fields.

January 28, 2024: Multiple Biopsies of bladder (CT-guided): Histology confirmed urachal adenocarcinoma. Molecular panel sequencing revealed mutations: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6).

February 1, 2024: Initiated chemotherapy with Cisplatin + 5-FU.

April 23, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, now measuring approximately 4.5 cm in diameter. Increased evidence of local invasion into surrounding structures. Several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, now measuring 2.0 cm. Chest CT scan: Increased number and size of metastatic lesions in both lungs. The largest metastasis is located peripherally in the left lung and now measures approximately 4.0 cm in diameter. Numerous other metastatic nodules, with some showing an increase in size, are scattered throughout both lung fields.

April 25, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,500/mcL, platelet count 250,000/mcL, total bilirubin 0.8 mg/dL, AST/ALT within normal limits, creatinine 0.8 mg/dL, hemoglobin 14.0 g/dL, serum albumin 4.0 g/dL, lipase and amylase within normal limits. Serum HCG test negative.

April 28, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies. Patient in good clinical condition, willing to participate in a trial.

===== Patient 2.1.1 =====

Patient Information
Name: Sarah Mitchell
Born: June 12, 1998
Address: 8765 Pine Street, Springfield, IL

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV urachal adenocarcinoma; m+ (LYM, PULMONARY)
Initial Detection: January 18, 2024, following persistent hematuria and abdominal discomfort
Biopsy Date: January 28, 2024
Molecular Profile: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6)

Therapy Overview
Chemotherapy: Began February 1 - April 22, 2024 (Cisplatin + 5-FU)

Comorbidities

Seasonal Allergies

Platin-induced Neuropathy (April 2024)

Medication

Cetirizine 10mg as needed

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

January 18, 2024: Presented with hematuria and abdominal discomfort. Abdominal ultrasound revealed a mass in the bladder dome.

January 22, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, measuring approximately 3.0 cm in diameter. Evidence of local invasion into surrounding structures + several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, measuring 1.5 cm.

Chest CT scan: Multiple metastatic lesions are present in both lungs. The largest metastasis is located peripherally in the left lung and measures approximately 3.1 cm in diameter. Other smaller metastatic nodules scattered throughout both lung fields.

January 28, 2024: Multiple Biopsies of bladder (CT-guided): Histology confirmed urachal adenocarcinoma. Molecular panel sequencing revealed mutations: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6).

February 1, 2024: Initiated chemotherapy with Cisplatin + 5-FU.
Chemotherapy abrogated before completion of the last cycle due to severe
neuropathy limiting daily activities.

April 23, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, now measuring approximately 4.5 cm in diameter. Increased evidence of local invasion into surrounding structures. Several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, now measuring 2.0 cm. Chest CT scan: Increased number and size of metastatic lesions in both lungs. The largest metastasis is located peripherally in the left lung and now measures approximately 4.0 cm in diameter. Numerous other metastatic nodules, with some showing an increase in size, are scattered throughout both lung fields.

cMRI: 1 single brain metastasis in the frontal lobe.

April 25, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,500/mcL, platelet count 250,000/mcL, total bilirubin 0.8 mg/dL, AST/ALT within normal limits, creatinine 0.8 mg/dL, hemoglobin 14.0 g/dL, serum albumin 4.0 g/dL, lipase and amylase within normal limits. Serum HCG test negative.

April 28, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.
Patient in overall good clinical condition, however persistent neuropathy
(no improvements). She is willing to participate in clinical trials.

===== Patient 2.1.2 =====

Patient Information
Name: Sarah Mitchell
Born: June 12, 1998
Address: 8765 Pine Street, Springfield, IL

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV urachal adenocarcinoma; m+ (LYM, PULMONARY)
Initial Detection: January 18, 2024, following persistent hematuria and abdominal discomfort
Biopsy Date: January 28, 2024
Molecular Profile: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6)

Therapy Overview
Chemotherapy: Began February 1 - April 22, 2024 (Cisplatin + 5-FU)

Comorbidities

Diabetes type II

Seasonal Allergies

Medication

Cetirizine 10mg as needed
Ceftriaxone 1g 1-0-0
Metformin 500mg BID (paused)
Glyburide 5mg BID (paused)
Insulin under monitoring

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

January 18, 2024: Presented with hematuria and abdominal discomfort. Abdominal ultrasound revealed a mass in the bladder dome.

January 22, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, measuring approximately 3.0 cm in diameter. Evidence of local invasion into surrounding structures + several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, measuring 1.5 cm.

Chest CT scan: Multiple metastatic lesions are present in both lungs. The largest metastasis is located peripherally in the left lung and measures approximately 3.1 cm in diameter. Other smaller metastatic nodules scattered throughout both lung fields.

January 28, 2024: Multiple Biopsies of bladder (CT-guided): Histology confirmed urachal adenocarcinoma. Molecular panel sequencing revealed mutations: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6).

February 1, 2024: Initiated chemotherapy with Cisplatin + 5-FU.

April 23, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, now measuring approximately 4.5 cm in diameter. Increased evidence of local invasion into surrounding structures. Several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, now measuring 2.0 cm. Chest CT scan: Increased number and size of metastatic lesions in both lungs. The largest metastasis is located peripherally in the left lung and now measures approximately 4.0 cm in diameter. Numerous other metastatic nodules, with some showing an increase in size, are scattered throughout both lung fields.

April 25, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,500/mcL, platelet count 250,000/mcL, total bilirubin 0.8 mg/dL, AST/ALT within normal limits, creatinine 0.8 mg/dL, hemoglobin 14.0 g/dL, serum albumin 4.0 g/dL, lipase and amylase within normal limits. Serum HCG test negative.

April 28, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies. Patient in good clinical condition, willing to participate in a trial.

May 1, 2024: Patient presents with fever, flank pain, and dysuria.
Hospitalized for further evaluation and treatment.
Ultrasound: Enlarged kidney with signs of
inflammation, consistent with pyelonephritis.
Blood culture: Pending. Urine culture: Pending. Started on IV antibiotics:
Ceftriaxone 1g.  CRP: 15 mg/dL. Leukocytes: 18,000/mcL. HbA1c 8.3%.
Paused Metformin/Glyburide, started on insulin with close monitoring

===== Patient 2.2 =====

Patient Information
Name: Sarah Mitchell
Born: June 12, 1998
Address: 8765 Pine Street, Springfield, IL

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV urachal adenocarcinoma; m+ (LYM, PULMONARY)
Initial Detection: January 18, 2024, following persistent hematuria and abdominal discomfort
Biopsy Date: January 28, 2024
Molecular Profile: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6)

Therapy Overview
Chemotherapy: Began February 1 - April 22, 2024 (Cisplatin + 5-FU)

Comorbidities

Seasonal Allergies

Medication

Cetirizine 10mg as needed

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

January 18, 2024: Presented with hematuria and abdominal discomfort. Abdominal ultrasound revealed a mass in the bladder dome.

January 22, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, measuring approximately 3.0 cm in diameter. Evidence of local invasion into surrounding structures + several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, measuring 1.5 cm.

Chest CT scan: Multiple metastatic lesions are present in both lungs. The largest metastasis is located peripherally in the left lung and measures approximately 3.1 cm in diameter. Other smaller metastatic nodules scattered throughout both lung fields.

January 28, 2024: Multiple Biopsies of bladder (CT-guided): Histology confirmed urachal adenocarcinoma. Molecular panel sequencing revealed mutations: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6).

February 1, 2024: Initiated chemotherapy with Cisplatin + 5-FU.

April 23, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, now measuring approximately 4.5 cm in diameter. Increased evidence of local invasion into surrounding structures. Several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, now measuring 2.0 cm. Chest CT scan: Increased number and size of metastatic lesions in both lungs. The largest metastasis is located peripherally in the left lung and now measures approximately 4.0 cm in diameter. Numerous other metastatic nodules, with some showing an increase in size, are scattered throughout both lung fields.

April 25, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,500/mcL, platelet count 250,000/mcL, total bilirubin 0.8 mg/dL, AST/ALT within normal limits, creatinine 0.8 mg/dL, hemoglobin 14.0 g/dL, serum albumin 4.0 g/dL, lipase and amylase within normal limits. Serum HCG test negative.

April 28, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies. Patient in good clinical condition, willing to participate in a trial.

===== Patient 2.2.1 =====

Patient Information
Name: Sarah Mitchell
Born: June 12, 1998
Address: 8765 Pine Street, Springfield, IL

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV urachal adenocarcinoma; m+ (LYM, PULMONARY)
Initial Detection: January 18, 2024, following persistent hematuria and abdominal discomfort
Biopsy Date: January 28, 2024
Molecular Profile: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6)

Therapy Overview
Chemotherapy: Began February 1 - April 22, 2024 (Cisplatin + 5-FU)

Comorbidities

Seasonal Allergies

Recurrent gastrointestinal bleedings due to tumor infiltration of the rectum,
requiring transfusions

Medication

Cetirizine 10mg as needed

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

January 18, 2024: Presented with hematuria and abdominal discomfort. Abdominal ultrasound revealed a mass in the bladder dome.

January 22, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, measuring approximately 3.0 cm in diameter. Evidence of local invasion into surrounding structures + several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, measuring 1.5 cm.

Chest CT scan: Multiple metastatic lesions are present in both lungs. The largest metastasis is located peripherally in the left lung and measures approximately 3.1 cm in diameter. Other smaller metastatic nodules scattered throughout both lung fields.

January 28, 2024: Multiple Biopsies of bladder (CT-guided): Histology confirmed urachal adenocarcinoma. Molecular panel sequencing revealed mutations: KRAS p.G12V, BCORL p.R1332*, TP53 p.H214fs7, CDKN2C p.L65F, MAP3K1 p.T949_E950insT, MYCN p.E47fs8, CTNNA1 p.K577_L578>TKL, JAK1 p.I597M, FANCL p.T367fs*12+, PIK3CA amplification (n>6), MYC amplification (n>6), MYCL1 amplification (n>6), SOX2 amplification (n>6), MUTYH amplification (n>6).

February 1, 2024: Initiated chemotherapy with Cisplatin + 5-FU.

April 23, 2024: CT scan abdomen/pelvis: Mass located at the bladder dome, now measuring approximately 4.5 cm in diameter. Rectal tumor invasion. Increased evidence of local invasion into surrounding structures. Several enlarged local lymph nodes are noted, with the largest lymph node located near the pelvic sidewall, now measuring 2.0 cm. Chest CT scan: Increased number and size of metastatic lesions in both lungs. The largest metastasis is located peripherally in the left lung and now measures approximately 4.0 cm in diameter. Numerous other metastatic nodules, with some showing an increase in size, are scattered throughout both lung fields.

April 25, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,500/mcL, platelet count 250,000/mcL, total bilirubin 0.8 mg/dL, AST/ALT within normal limits, creatinine 0.8 mg/dL, hemoglobin 8.4 g/dL
(due to recurrent GI bleedings), serum albumin 4.0 g/dL, lipase and amylase within normal limits. Serum HCG test negative.

April 28, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies. Patient in good clinical condition, willing to participate in a trial.

===== Patient 3.1 =====

Patient Information
Name: Thomas Meyer
Born: January 12, 1966
Address: Schlossallee 1, Dresden, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Masaoka-Koga Stage IVb thymic adenocarcinoma (metastases to the lungs, liver and spines T6, T9, L3)
Initial Detection: March 15, 2023, following persistent chest pain and cough, shortness-of-breath

Biopsy Date: March 28, 2023
Molecular Profile: Germline: BRCA2 p.K3326* (1N); Tumor: SMAD4 p.C363R (1N), TP53 p.305fs (2N_LOH), CDKN1B p.K100N (2N_LOH), ATM p.E1666* (4N), MAP3K8 p.H236Y (1N), TRAF1 p.R70H (2N), HDAC2 p.R409* (1N), TMEM111-TDRD3 fusion, PRKDC-CDH17 fusion, EXT1-MAGI2 fusion; Overexpressed genes: ERBB2, ERBB3, PDGFRB, TGFA, EGF, FGFR3, MET.

Therapy Overview
Initial Treatment:
Chemotherapy: Began April 5, 2023, with combination of Doxorubicin, Cisplatin, Vincristine and Cyclophosphamide (ADOC). Partial response after the initial two chemotherapy cycles completed by June, 2023. Continued chemotherapy until November 2023 (progressive disease).
Subsequent Treatment: Second-line treatment with Carboplatin plus Paclitaxel starting Nov 24, 2023. Current Status: Disease progression as of May 2024, with new metastatic lesions in the lungs.

Comorbidities

Former Smoker 25 py

Hypertension Stage 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Gastroesophageal Reflux Disease (GERD)

H/o cholecystectomy 2011

Medication

Losartan 50mg once daily

HCT 12.5mg once daily

Metformin 1000mg once daily

Atorvastatin 40mg once daily

Omeprazole 20mg once daily

XGEVA

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

March 15, 2023: Presented with persistent chest pain and cough and SOB.

March 20, 2023: CT scan of the chest: Mass in the anterior mediastinum measuring approximately 6.0 cm with evidence of local invasion into surrounding structures. Multiple pulmonary nodules suggestive of metastasis.

March 28, 2023: CT-guided biopsy of mediastinal mass. Histology confirmed thymic adenocarcinoma. Whole exome sequencing revealed germline mutation BRCA2 p.K3326*, tumor mutations: SMAD4 p.C363R, TP53 p.305fs, CDKN1B p.K100N, ATM p.E1666*, MAP3K8 p.H236Y, TRAF1 p.R70H, HDAC2 p.R409*, TMEM111-TDRD3 fusion, PRKDC-CDH17 fusion, EXT1-MAGI2 fusion. Overexpressed genes: ERBB2, ERBB3, PDGFRB, TGFA, EGF, FGFR3, MET.

April 5, 2023: Initiated chemotherapy with Doxorubicin, Cisplatin, Vincristine and Cyclophosphamide (ADOC). Patient in sophisticated conditions, first therapy today.

June 20, 2023: Follow-up CT scan showed partial response with a decrease in the size of the primary tumor and pulmonary nodules. Continued chemotherapy regimen.

November 15, 2023: Follow-up imaging CT chest/abdomen: disease progression with new metastatic lesions. Multiple hepatic lesions, with the largest lesion in segment VIII measuring 4.5 cm, and another lesion in segment II measuring 3.0 cm. Bone scan indicates metastatic involvement of the spine, with lesions identified at T6, T9, and L3 vertebrae. Additional findings include new pulmonary nodules and further enlargement of the primary mass in the anterior mediastinum.

November 24, 2023: Started second-line therapy with Carboplatin plus Paclitaxel.

March 10, 2024: Follow-up CT scan: PD. Progression of disease with increased size of liver metastases and new bone lesions.

May 20, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

June 1, 2024: Detailed assessment of health status confirmed adequate organ function. All routine labs within normal limits.

===== Patient 3.1.1 =====

Patient Information
Name: Thomas Meyer
Born: January 12, 1966
Address: Schlossallee 1, Dresden, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Masaoka-Koga Stage IVb thymic adenocarcinoma (metastases to the lungs, liver and spines T6, T9, L3)
Initial Detection: March 15, 2023, following persistent chest pain and cough, shortness-of-breath

Biopsy Date: March 28, 2023
Molecular Profile: Germline: BRCA2 p.K3326* (1N); Tumor: SMAD4 p.C363R (1N), TP53 p.305fs (2N_LOH), CDKN1B p.K100N (2N_LOH), ATM p.E1666* (4N), MAP3K8 p.H236Y (1N), TRAF1 p.R70H (2N), HDAC2 p.R409* (1N), TMEM111-TDRD3 fusion, PRKDC-CDH17 fusion, EXT1-MAGI2 fusion; Overexpressed genes: ERBB2, ERBB3, PDGFRB, TGFA, EGF, FGFR3, MET.

Therapy Overview
Initial Treatment:
Chemotherapy: Began April 5, 2023, with combination of Doxorubicin, Cisplatin, Vincristine and Cyclophosphamide (ADOC). Partial response after the initial two chemotherapy cycles completed by June, 2023. Continued chemotherapy until November 2023 (progressive disease).
Subsequent Treatment: Second-line treatment with Carboplatin plus Paclitaxel starting Nov 24, 2023. Current Status: Disease progression as of May 2024, with new metastatic lesions in the lungs.

Comorbidities

Former Smoker 25 py

Interstitial Lung disease (ILD)

Hypertension Stage 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Gastroesophageal Reflux Disease (GERD)

H/o cholecystectomy 2011

Medication

Prednisone 10mg 1x

Losartan 50mg once daily

HCT 12.5mg once daily

Metformin 1000mg 1x/d

Atorvastatin 40mg once daily

Omeprazole 20mg daily

XGEVA q4w

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

March 15, 2023: Presented with persistent chest pain and cough and SOB.

March 20, 2023: CT scan of the chest: Mass in the anterior mediastinum measuring approximately 6.0 cm with evidence of local invasion into surrounding structures. Multiple pulmonary nodules suggestive of metastasis. Evidence of known Interstitial Lung Disease (ILD) with diffuse interstitial
markings and fibrosis.

March 28, 2023: CT-guided biopsy of mediastinal mass. Histology confirmed thymic adenocarcinoma. Whole exome sequencing revealed germline mutation BRCA2 p.K3326*, tumor mutations: SMAD4 p.C363R, TP53 p.305fs, CDKN1B p.K100N, ATM p.E1666*, MAP3K8 p.H236Y, TRAF1 p.R70H, HDAC2 p.R409*, TMEM111-TDRD3 fusion, PRKDC-CDH17 fusion, EXT1-MAGI2 fusion. Overexpressed genes: ERBB2, ERBB3, PDGFRB, TGFA, EGF, FGFR3, MET.

April 5, 2023: Initiated chemotherapy with Doxorubicin, Cisplatin, Vincristine and Cyclophosphamide (ADOC). Patient in sophisticated conditions, first therapy today.

June 20, 2023: Follow-up CT scan showed partial response with a decrease in the size of the primary tumor and pulmonary nodules. Continued chemotherapy regimen.

November 15, 2023: Follow-up imaging CT chest/abdomen: disease progression with new metastatic lesions. Multiple hepatic lesions, with the largest lesion in segment VIII measuring 4.5 cm, and another lesion in segment II measuring 3.0 cm. Bone scan indicates metastatic involvement of the spine, with lesions identified at T6, T9, and L3 vertebrae. Additional findings include new pulmonary nodules and further enlargement of the primary mass in the anterior mediastinum. Signs of known ILD, stable.

November 24, 2023: Started second-line therapy with Carboplatin plus Paclitaxel.

March 10, 2024: Follow-up CT scan: PD. Progression of disease with increased size of liver metastases and new bone lesions.

May 20, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

June 1, 2024: Detailed assessment of health status confirmed adequate organ function. All routine labs within normal limits.

Patient Information
Name: Thomas Meyer
Born: January 12, 1966
Address: Schlossallee 1, Dresden, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Masaoka-Koga Stage IVb thymic adenocarcinoma (metastases to the lungs, liver and spines T6, T9, L3)
Initial Detection: March 15, 2023, following persistent chest pain and cough, shortness-of-breath

Biopsy Date: March 28, 2023
Molecular Profile: Germline: BRCA2 p.K3326* (1N); Tumor: SMAD4 p.C363R (1N), TP53 p.305fs (2N_LOH), CDKN1B p.K100N (2N_LOH), ATM p.E1666* (4N), MAP3K8 p.H236Y (1N), TRAF1 p.R70H (2N), HDAC2 p.R409* (1N), TMEM111-TDRD3 fusion, PRKDC-CDH17 fusion, EXT1-MAGI2 fusion; Overexpressed genes: ERBB2, ERBB3, PDGFRB, TGFA, EGF, FGFR3, MET.

Therapy Overview
Initial Treatment:
Chemotherapy: Began April 5, 2023, with combination of Doxorubicin, Cisplatin, Vincristine and Cyclophosphamide (ADOC). Partial response after the initial two chemotherapy cycles completed by June, 2023. Continued chemotherapy until November 2023 (progressive disease).
Subsequent Treatment: Second-line treatment with Carboplatin plus Paclitaxel starting Nov 24, 2023. Current Status: Disease progression as of May 2024, with new metastatic lesions in the lungs.

Comorbidities

Coronary Artery Disease (CAD), status post percutaneous coronary intervention

(PCI) with stent placement in 2018

Interstitial Lung disease (ILD)

Hypertension Stage 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Gastroesophageal Reflux Disease (GERD)

H/o cholecystectomy 2011

Former Smoker 25 py

Medication

Aspirin 100 1-0-0
Clopidogrel 75mg 1-0-0
Prednisone 10mg 1x

Losartan 50mg once daily

HCT 12.5mg once daily

Metformin 1000mg 1x/d

Atorvastatin 40mg once daily

Omeprazole 20mg daily

XGEVA q4w

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

March 15, 2023: Presented with persistent chest pain and cough and SOB.

March 20, 2023: CT scan of the chest: Mass in the anterior mediastinum measuring approximately 6.0 cm with evidence of local invasion into surrounding structures. Multiple pulmonary nodules suggestive of metastasis. Evidence of known Interstitial Lung Disease (ILD) with diffuse interstitial
markings and fibrosis.

March 28, 2023: CT-guided biopsy of mediastinal mass. Histology confirmed thymic adenocarcinoma. Whole exome sequencing revealed germline mutation BRCA2 p.K3326*, tumor mutations: SMAD4 p.C363R, TP53 p.305fs, CDKN1B p.K100N, ATM p.E1666*, MAP3K8 p.H236Y, TRAF1 p.R70H, HDAC2 p.R409*, TMEM111-TDRD3 fusion, PRKDC-CDH17 fusion, EXT1-MAGI2 fusion. Overexpressed genes: ERBB2, ERBB3, PDGFRB, TGFA, EGF, FGFR3, MET.

April 5, 2023: Initiated chemotherapy with Doxorubicin, Cisplatin, Vincristine and Cyclophosphamide (ADOC). Patient in sophisticated conditions, first therapy today.

June 20, 2023: Follow-up CT scan showed partial response with a decrease in the size of the primary tumor and pulmonary nodules. Continued chemotherapy regimen.

November 15, 2023: Follow-up imaging CT chest/abdomen: disease progression with new metastatic lesions. Multiple hepatic lesions, with the largest lesion in segment VIII measuring 4.5 cm, and another lesion in segment II measuring 3.0 cm. Bone scan indicates metastatic involvement of the spine, with lesions identified at T6, T9, and L3 vertebrae. Additional findings include new pulmonary nodules and further enlargement of the primary mass in the anterior mediastinum. Signs of known ILD, stable.

November 24, 2023: Started second-line therapy with Carboplatin plus Paclitaxel.

March 10, 2024: Follow-up CT scan: PD. Progression of disease with increased size of liver metastases and new bone lesions.

May 20, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

June 1, 2024: Detailed assessment of health status confirmed adequate organ function. All routine labs within normal limits. Patient claims newly intermittent chest pain -> next week appointment at in-house cardiology department.

===== Patient 3.2 =====

Patient Information
Name: Tim Müller
Born: January 03, 1966
Address: Parkallee 10, Dresden, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Masaoka-Koga Stage IVb thymic adenocarcinoma (metastases to the lungs, liver and spines T6, T9, L3)
Initial Detection: March 15, 2023, following persistent chest pain and cough, shortness-of-breath

Biopsy Date: March 28, 2023
Molecular Profile: Germline: del BRCA2 mutation; Tumor: SMAD4 p.C363R (1N), TP53 p.305fs (2N_LOH), CDKN1B p.K100N (2N_LOH), ATM p.E1666* (4N), MAP3K8 p.H236Y (1N), TRAF1 p.R70H (2N), HDAC2 p.R409* (1N), TMEM111-TDRD3 fusion, PRKDC-CDH17 fusion, EXT1-MAGI2 fusion; Overexpressed genes: ERBB2, ERBB3, PDGFRB, TGFA, EGF, FGFR3, MET.

Therapy Overview
Initial Treatment:
Chemotherapy: Began April 5, 2023, with combination of Doxorubicin, Cisplatin, Vincristine and Cyclophosphamide (ADOC). Partial response after the initial two chemotherapy cycles completed by June, 2023. Continued chemotherapy until November 2023 (progressive disease).
Subsequent Treatment: Second-line treatment with Carboplatin plus Paclitaxel starting Nov 24, 2023. Current Status: Disease progression as of May 2024, with new metastatic lesions in the lungs.

Comorbidities

Former Smoker 25 py

Hypertension Stage 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Gastroesophageal Reflux Disease (GERD)

H/o cholecystectomy 2011

Medication

Losartan 50mg once daily

HCT 12.5mg once daily

Metformin 1000mg once daily

Atorvastatin 40mg once daily

Omeprazole 20mg once daily

XGEVA

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

March 15, 2023: Presented with persistent chest pain and cough and SOB.

March 20, 2023: CT scan of the chest: Mass in the anterior mediastinum measuring approximately 6.0 cm with evidence of local invasion into surrounding structures. Multiple pulmonary nodules suggestive of metastasis.

March 28, 2023: CT-guided biopsy of mediastinal mass. Histology confirmed thymic adenocarcinoma. Whole exome sequencing revealed: germline BRCA2 mutation (del), tumor mutations: SMAD4 p.C363R, TP53 p.305fs, CDKN1B p.K100N, ATM p.E1666*, MAP3K8 p.H236Y, TRAF1 p.R70H, HDAC2 p.R409*, TMEM111-TDRD3 fusion, PRKDC-CDH17 fusion, EXT1-MAGI2 fusion. Overexpressed genes: ERBB2, ERBB3, PDGFRB, TGFA, EGF, FGFR3, MET.

April 5, 2023: Initiated chemotherapy with Doxorubicin, Cisplatin, Vincristine and Cyclophosphamide (ADOC). Patient in sophisticated conditions, first therapy today.

June 20, 2023: Follow-up CT scan showed partial response with a decrease in the size of the primary tumor and pulmonary nodules. Continued chemotherapy regimen.

November 15, 2023: Follow-up imaging CT chest/abdomen: disease progression with new metastatic lesions. Multiple hepatic lesions, with the largest lesion in segment VIII measuring 4.5 cm, and another lesion in segment II measuring 3.0 cm. Bone scan indicates metastatic involvement of the spine, with lesions identified at T6, T9, and L3 vertebrae. Additional findings include new pulmonary nodules and further enlargement of the primary mass in the anterior mediastinum.

November 24, 2023: Started second-line therapy with Carboplatin plus Paclitaxel.

March 8, 2024: End of chemotherapy.

March 10, 2024: Follow-up CT scan: PD. Progression of disease with increased size of liver metastases and new bone lesions.

March 20, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

April 5, 2024: Detailed assessment of health status confirmed adequate organ function. All routine labs within normal limits.

===== Patient 4.1 =====

Patient Information

Name: David Gärtner

Born: March 22, 1965

Address: Cologne, Domstrasse 1, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IV oropharyngeal carcinoma (Metastatic: LYM, HEP, OSS)

Initial Detection: February 10, 2023, following persistent sore throat and difficulty swallowing

Biopsy Date: February 20, 2023

Molecular Profile: PIK3CA p.E545K (AF 25%), MAPK1 p.E322K (AF 10%), FGFR3 p.D786N (AF 30%)

Therapy Overview

Initial Treatment:

Radiochemotherapy: Began March 1, 2023, with a regimen of Cisplatin (200 mg/m2) paired with local radiotherapy (70G). Partial response noted after the initial radiochemotherapy completed by June 15, 2023. Follow-up CT scan shows disease progression in September 2024.

Subsequent Treatment: Began September 15, immunotherapy with Nivolumab (240mg/2weeks).

Current Status: Disease progression as of March 2024, with new metastatic lesions identified. ECOG 1.

Comorbidities

Active Smoker 50 py

Hypertension Stage 1

Hyperlipidemia

Peripheral artery disease Fontaine 2a

Diverticular disease CDD 3a

Medication

Lisinopril 20mg 1-0-0

Simvastatin 20mg 0-0-0-1

XGEVA, Vitamin D

Chronological Medical Findings:

February 10, 2023: Presented with persistent sore throat and difficulty swallowing. CT scan of the neck revealed a suspicious mass in the oropharynx.

February 15, 2023: CT scan of the neck: Mass in the oropharynx measuring approximately 4.5 cm with evidence of local invasion into surrounding structures. Multiple enlarged cervical lymph nodes are noted, with the largest measuring approximately 2.2 cm in the right level II region. These nodes exhibit round morphology and loss of the fatty hilum, characteristics suggestive of metastatic involvement. Additional enlarged lymph nodes are present in the levels III and IV on the right side.

February 18, 2023: Staging CT (chest and abdomen): No signs of distant metastasis.

February 20, 2023: Biopsy of the oropharyngeal mass performed. Histology confirmed oropharyngeal carcinoma. Molecular panel sequencing revealed mutations: PIK3CA p.E545K (AF 25%), MAPK1 p.E322K (AF 10%), FGFR3 p.D786N (AF 30%). Tumor purity was 60%.

March 1, 2024: Initiated radiochemotherapy with Cisplatin and 5-Fluorouracil alongside local radiotherapy (70G).

June 15, 2023: Follow-up CT scan showed partial response with a decrease in the size of the primary tumor and cervical lymph nodes.

September 10, 2023: Follow-up imaging CT Neck/Chest/Abdomen: Disease progression (PD). Several new hypodense lesions identified in the liver: The largest lesion located in segment VI, measuring approximately 3.1 cm in diameter. Smaller lesions scattered throughout the right  hepatic lobe. Multiple new pulmonary nodules are detected in both lungs. The largest nodule located in the right lower lobe, measuring approximately 1.5 cm in diameter. Additional smaller nodules are distributed throughout the bilateral lung fields. No evidence of pleural effusion or pneumothorax. The oropharyngeal mass remains present, with no significant change in size compared to the previous scan. The previously noted enlarged cervical lymph nodes remain prominent, with no significant interval change in size or number.

September 15, 2023: Began immunotherapy with Nivolumab.

December 18, 2023: Follow-up CT scan Neck/Chest/abdomen: Stable disease.

December-February 2023: Continuation Nivolumab.

February 20, 2024: Follow-up CT scan Neck/Chest/Abdomen: Progression of disease. Enlargement of multiple known hypodense lesions in the liver, with the largest now measuring 4.5 cm in segment VI (previously 3.1cm). New lytic lesions in the pelvis. Previously noted pulmonary nodules remain stable with no significant interval change. Stable primary tumor and cervical lymphadenopathy.

March 3, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

March 10, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,500/mcL, platelet count 250,000/mcL, total bilirubin 0.8 mg/dL, AST/ALT within normal limits, creatinine 0.8 mg/dL, hemoglobin 14.0 g/dL, serum albumin 4.0 g/dL, lipase and amylase within normal limits. Patient in good clinical condition.

Patient Information

Name: David Gärtner

Born: March 22, 1965

Address: Cologne, Domstrasse 1, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IV oropharyngeal carcinoma (Metastatic: LYM, HEP, OSS)

Initial Detection: February 10, 2023, following persistent sore throat and difficulty swallowing

Biopsy Date: February 20, 2023

Molecular Profile: PIK3CA p.E545K (AF 25%), MAPK1 p.E322K (AF 10%), FGFR3 p.D786N (AF 30%)

Therapy Overview

Initial Treatment:

Radiochemotherapy: Began March 1, 2023, with a regimen of Cisplatin (200 mg/m2) paired with local radiotherapy (70G). Partial response noted after the initial radiochemotherapy completed by June 15, 2023. Follow-up CT scan shows disease progression in September 2024.

Subsequent Treatment: Began September 15, immunotherapy with Nivolumab (240mg/2weeks).

Current Status: Disease progression as of March 2024, with new metastatic lesions identified. ECOG 1.

Comorbidities

Active Smoker 50 py

Hypertension Stage 1

Hyperlipidemia

Peripheral artery disease Fontaine 2a

Diverticular disease CDD 3a

Medication

Lisinopril 20mg 1-0-0

Simvastatin 20mg 0-0-0-1

XGEVA, Vitamin D

Chronological Medical Findings:

February 10, 2023: Presented with persistent sore throat and difficulty swallowing. CT scan of the neck revealed a suspicious mass in the oropharynx.

February 15, 2023: CT scan of the neck: Mass in the oropharynx measuring approximately 4.5 cm with evidence of local invasion into surrounding structures. Multiple enlarged cervical lymph nodes are noted, with the largest measuring approximately 2.2 cm in the right level II region. These nodes exhibit round morphology and loss of the fatty hilum, characteristics suggestive of metastatic involvement. Additional enlarged lymph nodes are present in the levels III and IV on the right side.

February 18, 2023: Staging CT (chest and abdomen): No signs of distant metastasis.

February 20, 2023: Biopsy of the oropharyngeal mass performed. Histology confirmed oropharyngeal carcinoma. Molecular panel sequencing revealed mutations: PIK3CA p.E545K (AF 25%), MAPK1 p.E322K (AF 10%), FGFR3 p.D786N (AF 30%). Tumor purity was 60%.

March 1, 2024: Initiated radiochemotherapy with Cisplatin and 5-Fluorouracil alongside local radiotherapy (70G).

June 15, 2023: Follow-up CT scan showed partial response with a decrease in the size of the primary tumor and cervical lymph nodes.

September 10, 2023: Follow-up imaging CT Neck/Chest/Abdomen: Disease progression (PD). Several new hypodense lesions identified in the liver: The largest lesion located in segment VI, measuring approximately 3.1 cm in diameter. Smaller lesions scattered throughout the right  hepatic lobe. Multiple new pulmonary nodules are detected in both lungs. The largest nodule located in the right lower lobe, measuring approximately 1.5 cm in diameter. Additional smaller nodules are distributed throughout the bilateral lung fields. No evidence of pleural effusion or pneumothorax. The oropharyngeal mass remains present, with no significant change in size compared to the previous scan. The previously noted enlarged cervical lymph nodes remain prominent, with no significant interval change in size or number.

September 15, 2023: Began immunotherapy with Nivolumab.

December 18, 2023: Follow-up CT scan Neck/Chest/abdomen: Stable disease.

December-February 2023: Continuation Nivolumab.

February 20, 2024: Follow-up CT scan Neck/Chest/Abdomen: Progression of disease. Enlargement of multiple known hypodense lesions in the liver, with the largest now measuring 4.5 cm in segment VI (previously 3.1cm). New lytic lesions in the pelvis. Previously noted pulmonary nodules remain stable with no significant interval change. Stable primary tumor and cervical lymphadenopathy.

March 3, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

March 10, 2024: Visit in the Emergency department with fever for 3 days,
shortness of breath + cough + severe headaches.
Routine labs: ANC 15,000/mcL, platelet count 200,000/mcL,
total bilirubin 1.2mg/dL, AST/ALT 1.5 x ULN, creatinine 1.1 mg/dL,
hemoglobin 12.0 g/dL, serum albumin 3.5 g/dL, leukocytes 18,000/mcL,
CRP 23 mg/dL.
Chest X-ray and CT scan confirmed pneumonia.
Hospitalized for further evaluation and treatment.
Blood and sputum cultures were taken and are pending.
Patient started on IV antibiotics: Ceftriaxone and Azithromycin.

===== Patient 4.1.2 =====

Patient Information

Name: David Gärtner

Born: March 22, 1965

Address: Cologne, Domstrasse 1, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IV oropharyngeal carcinoma (Metastatic: LYM, HEP, OSS)

Initial Detection: February 10, 2023, following persistent sore throat and difficulty swallowing

Biopsy Date: February 20, 2023

Molecular Profile: PIK3CA p.E545K (AF 25%), MAPK1 p.E322K (AF 10%), FGFR3 p.D786N (AF 30%)

Therapy Overview

Initial Treatment:

Radiochemotherapy: Began March 1, 2023, with a regimen of Cisplatin (200 mg/m2) paired with local radiotherapy (70G). Partial response noted after the initial radiochemotherapy completed by June 15, 2023. Follow-up CT scan shows disease progression in September 2024.

Subsequent Treatment: Began September 15, immunotherapy with Nivolumab (240mg/2weeks).

Current Status: Disease progression as of March 2024, with new metastatic lesions identified. ECOG 1.

Comorbidities

Active Smoker 50 py

Hypertension Stage 1

Hyperlipidemia

Peripheral artery disease Fontaine 2a

Diverticular disease CDD 3a

Epilepsy, Focal Onset Impaired Awareness Seizures
NYHA Class II Heart Failure
COPD, GOLD Stage 3 (Severe)

Medication

Levetiracetam 500mg 1-0-1 (for epilepsy)

Metoprolol Succinate 50mg 1-0-0 (for heart failure)

Tiotropium 18mcg 1-0-0 (for COPD)

Salbutamol Inhaler 100mcg as needed (for COPD)

Lisinopril 20mg 1-0-0

Simvastatin 20mg 0-0-0-1

XGEVA, Vitamin D

Chronological Medical Findings:

February 10, 2023: Presented with persistent sore throat and difficulty swallowing. CT scan of the neck revealed a suspicious mass in the oropharynx.

February 15, 2023: CT scan of the neck: Mass in the oropharynx measuring approximately 4.5 cm with evidence of local invasion into surrounding structures. Multiple enlarged cervical lymph nodes are noted, with the largest measuring approximately 2.2 cm in the right level II region. These nodes exhibit round morphology and loss of the fatty hilum, characteristics suggestive of metastatic involvement. Additional enlarged lymph nodes are present in the levels III and IV on the right side.

February 18, 2023: Staging CT (chest and abdomen): No signs of distant metastasis.

February 20, 2023: Biopsy of the oropharyngeal mass performed. Histology confirmed oropharyngeal carcinoma. Molecular panel sequencing revealed mutations: PIK3CA p.E545K (AF 25%), MAPK1 p.E322K (AF 10%), FGFR3 p.D786N (AF 30%). Tumor purity was 60%.

March 1, 2024: Initiated radiochemotherapy with Cisplatin and 5-Fluorouracil alongside local radiotherapy (70G).

June 15, 2023: Follow-up CT scan showed partial response with a decrease in the size of the primary tumor and cervical lymph nodes.

September 10, 2023: Follow-up imaging CT Neck/Chest/Abdomen: Disease progression (PD). Several new hypodense lesions identified in the liver: The largest lesion located in segment VI, measuring approximately 3.1 cm in diameter. Smaller lesions scattered throughout the right  hepatic lobe. Multiple new pulmonary nodules are detected in both lungs. The largest nodule located in the right lower lobe, measuring approximately 1.5 cm in diameter. Additional smaller nodules are distributed throughout the bilateral lung fields. No evidence of pleural effusion or pneumothorax. The oropharyngeal mass remains present, with no significant change in size compared to the previous scan. The previously noted enlarged cervical lymph nodes remain prominent, with no significant interval change in size or number.

September 15, 2023: Began immunotherapy with Nivolumab.

December 18, 2023: Follow-up CT scan Neck/Chest/abdomen: Stable disease.

December-February 2023: Continuation Nivolumab.

February 20, 2024: Follow-up CT scan Neck/Chest/Abdomen: Progression of disease. Enlargement of multiple known hypodense lesions in the liver, with the largest now measuring 4.5 cm in segment VI (previously 3.1cm). New lytic lesions in the pelvis. Previously noted pulmonary nodules remain stable with no significant interval change. Stable primary tumor and cervical lymphadenopathy.

March 3, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

March 10, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,500/mcL, platelet count 250,000/mcL, total bilirubin 0.8 mg/dL, AST/ALT within normal limits, creatinine 0.8 mg/dL, hemoglobin 14.0 g/dL, serum albumin 4.0 g/dL, lipase and amylase within normal limits. Patient in good clinical condition.

===== Patient 4.1.3 =====

Patient Information

Name: David Gärtner

Born: March 22, 1965

Address: Cologne, Domstrasse 1, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IV oropharyngeal carcinoma (Metastatic: LYM, HEP, OSS)

Initial Detection: February 10, 2023, following persistent sore throat and difficulty swallowing

Biopsy Date: February 20, 2023

Molecular Profile: PIK3CA p.E545K (AF 25%), MAPK1 p.E322K (AF 10%), FGFR3 p.D786N (AF 30%)

Therapy Overview

Initial Treatment:

Radiochemotherapy: Began March 1, 2023, with a regimen of Cisplatin (200 mg/m2) paired with local radiotherapy (70G). Partial response noted after the initial radiochemotherapy completed by June 15, 2023. Follow-up CT scan shows disease progression in September 2024.

Subsequent Treatment: Began September 15, immunotherapy with Nivolumab (240mg/2weeks).

Current Status: Disease progression as of March 2024, with new metastatic lesions identified. ECOG 1.

Comorbidities

Active hepatitis C virus (HCV) infection (HCV antibody +),
HCV RNA elevated (March 10, 2024)

Active Smoker 50 py

Alcoholic (6 bottles of beer / day) Regular marijuana use (up to 10 joints per day)

Hypertension Stage 1

Hyperlipidemia

Peripheral artery disease Fontaine 2a

Diverticular disease CDD 3a

Medication

Sofosbuvir/Velpatasvir 400mg/100mg 1-0-0

Lisinopril 20mg 1-0-0

Simvastatin 20mg 0-0-0-1

XGEVA, Vitamin D

Chronological Medical Findings:

February 10, 2023: Presented with persistent sore throat and difficulty swallowing. CT scan of the neck revealed a suspicious mass in the oropharynx.

February 15, 2023: CT scan of the neck: Mass in the oropharynx measuring approximately 4.5 cm with evidence of local invasion into surrounding structures. Multiple enlarged cervical lymph nodes are noted, with the largest measuring approximately 2.2 cm in the right level II region. These nodes exhibit round morphology and loss of the fatty hilum, characteristics suggestive of metastatic involvement. Additional enlarged lymph nodes are present in the levels III and IV on the right side.

February 18, 2023: Staging CT (chest and abdomen): No signs of distant metastasis.

February 20, 2023: Biopsy of the oropharyngeal mass performed. Histology confirmed oropharyngeal carcinoma. Molecular panel sequencing revealed mutations: PIK3CA p.E545K (AF 25%), MAPK1 p.E322K (AF 10%), FGFR3 p.D786N (AF 30%). Tumor purity was 60%.

March 1, 2024: Initiated radiochemotherapy with Cisplatin and 5-Fluorouracil alongside local radiotherapy (70G).

June 15, 2023: Follow-up CT scan showed partial response with a decrease in the size of the primary tumor and cervical lymph nodes.

September 10, 2023: Follow-up imaging CT Neck/Chest/Abdomen: Disease progression (PD). Several new hypodense lesions identified in the liver: The largest lesion located in segment VI, measuring approximately 3.1 cm in diameter. Smaller lesions scattered throughout the right  hepatic lobe. Multiple new pulmonary nodules are detected in both lungs. The largest nodule located in the right lower lobe, measuring approximately 1.5 cm in diameter. Additional smaller nodules are distributed throughout the bilateral lung fields. No evidence of pleural effusion or pneumothorax. The oropharyngeal mass remains present, with no significant change in size compared to the previous scan. The previously noted enlarged cervical lymph nodes remain prominent, with no significant interval change in size or number.

September 15, 2023: Began immunotherapy with Nivolumab.

December 18, 2023: Follow-up CT scan Neck/Chest/abdomen: Stable disease.

December-February 2023: Continuation Nivolumab.

February 20, 2024: Follow-up CT scan Neck/Chest/Abdomen: Progression of disease. Enlargement of multiple known hypodense lesions in the liver, with the largest now measuring 4.5 cm in segment VI (previously 3.1cm). New lytic lesions in the pelvis. Previously noted pulmonary nodules remain stable with no significant interval change. Stable primary tumor and cervical lymphadenopathy.

March 3, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

March 10, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,500/mcL, platelet count 250,000/mcL, total bilirubin 0.8 mg/dL, AST/ALT within normal limits, creatinine 0.8 mg/dL, hemoglobin 14.0 g/dL, serum albumin 4.0 g/dL, lipase and amylase within normal limits. HCV RNA at 2,500,000 IU/mL. Patient in good clinical condition.

===== Patient 5.1 =====

Patient Information

Name: Lisa Müller
Born: April 12, 1960
Address: Hamburg, Hafenstrasse 3, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV lung adenocarcinoma (M+: HEP, LYM, BONE, ADRENAL)
Initial Detection: January November 21, 2023, following persistent cough and weight loss
Biopsy Date: November 28, 2023

Molecular Profile: EGFR p.E746_A750del (AF 43%), TP53 p.A138_Q144del (AF 37%), MET Amplification FISH positive; Tumor Purity: 30%; Tumor Mutational Burden (TMB): 3.8 Mut/MB

Therapy Overview
Initial Treatment:
Chemotherapy: Began February December 2023, with a regimen of Pembrolizumab, Carboplatin and Pemetrexed. Partial response after the initial chemotherapy cycle completed by May 1, 2024. Continued chemotherapy until May 2024 (progressive disease).

Comorbidities

Hyperlipidemia

Osteoarthritis

Psoriasis vulgaris

H/o cholecystectomy 2007

45py

Medication

Atorvastatin 40mg once daily

Hydrocortisone cream

Ibuprofen 400mg as needed

XGEVA

Novalgin 500 2-2-2-2

Performance Status: ECOG Performance Status 1

Chronological Medical Findings:

November 8, 2023: Presented with persistent cough and weight loss (-6kg/3 mo) at her primary care physician. 1 week antibiotic treatment for suspected airway infection without clinical improvements, chest x-ray revealed tumorous lesion in the left lung.

November 21, 2023: CT scan of the chest: Mass in the left upper lobe measuring approximately 5.0 cm with evidence of local invasion into surrounding structures, including the left main bronchus and adjacent vascular structures. Enlarged mediastinal lymph nodes, particularly in the subcarinal and right paratracheal regions, with the largest node measuring 1.8 cm. Additional moderate pleural effusion on the left side. Multiple liver lesions suggestive of metastasis, with the largest lesion in segment VIII measuring 3.5 cm and another lesion in segment IVa measuring 2.2 cm. Adrenal metastasis on the left side. Bone metastases in C3, T3,4,7.

November 28, 2023: CT guided tumor biopsy: Histology confirmed lung adenocarcinoma. Molecular panel sequencing revealed mutations: EGFR p.E746_A750del (AF 43%), TP53 p.A138_Q144del (AF 37%), MET Amplification FISH positive. Tumor purity was 30%. Tumor Mutational Burden (TMB) was 3.8 Mut/MB.

December 5, 2023: Initiated chemotherapy with Carboplatin and Pemetrexed + immunotherapy with Pembrolizumab.

March 10, 2024: Follow-up CT scan: Partial Response. Continued chemotherapy regimen.

March - May 2024: Continued therapy with Carbo/Pem + Pembrolizumab.

May 07, 2024: CT-scan Chest/Abdomen: Significant disease progression. Mass in the left upper lobe has increased to approximately 6.5 cm with further invasion into the left main bronchus and adjacent vascular structures. Enlarged mediastinal lymph nodes are now more prominent, especially in the subcarinal and right paratracheal regions, with the largest node now measuring 2.5 cm. Progressive pleural effusion left > right.

Abdomen and Pelvis: Multiple liver lesions, with the largest in segment VIII now measuring 4.5 cm and another in segment IVa measuring 3.0 cm. New metastatic lesions observed in segments V and VI. The adrenal metastasis on the left side has increased in size to 2.5 cm.

Bone Metastases: Increased metastatic involvement with new lesions identified in the spine, including C2, T5, and L1, in addition to the previously noted C3, T3, T4, and T7.

May 10, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

May 15, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,800/mcL, platelet count 220,000/mcL, total bilirubin 0.9 mg/dL, AST/ALT within normal limits, creatinine 0.9 mg/dL, hemoglobin 13.5 g/dL, serum albumin 4.2 g/dL, lipase and amylase within normal limits.

===== Patient 5.1.1 =====

Patient Information

Name: Lisa Müller
Born: April 12, 1960
Address: Hamburg, Hafenstrasse 3, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: Stage IV lung adenocarcinoma (M+: HEP, LYM, BONE, ADRENAL)
Initial Detection: January November 21, 2023, following persistent cough and weight loss
Biopsy Date: November 28, 2023

Molecular Profile: EGFR p.E746_A750del (AF 43%), TP53 p.A138_Q144del (AF 37%), MET Amplification FISH positive; Tumor Purity: 30%; Tumor Mutational Burden (TMB): 3.8 Mut/MB

Therapy Overview
Initial Treatment:
Chemotherapy: Began February December 2023, with a regimen of Pembrolizumab, Carboplatin and Pemetrexed. Partial response after the initial chemotherapy cycle completed by May 1, 2024. Continued chemotherapy until May 2024 (progressive disease).

Comorbidities

Hyperlipidemia

Osteoarthritis

Psoriasis vulgaris

H/o cholecystectomy 2007

45py

Medication

Atorvastatin 40mg once daily

Hydrocortisone cream

Ibuprofen 400mg as needed

XGEVA

Novalgin 500 2-2-2-2

Prednisone 40mg daily

Performance Status: ECOG Performance Status 2

Chronological Medical Findings:

November 8, 2023: Presented with persistent cough and weight loss (-6kg/3 mo) at her primary care physician. 1 week antibiotic treatment for suspected airway infection without clinical improvements, chest x-ray revealed tumorous lesion in the left lung.

November 21, 2023: CT scan of the chest: Mass in the left upper lobe measuring approximately 5.0 cm with evidence of local invasion into surrounding structures, including the left main bronchus and adjacent vascular structures. Enlarged mediastinal lymph nodes, particularly in the subcarinal and right paratracheal regions, with the largest node measuring 1.8 cm. Additional moderate pleural effusion on the left side. Multiple liver lesions suggestive of metastasis, with the largest lesion in segment VIII measuring 3.5 cm and another lesion in segment IVa measuring 2.2 cm. Adrenal metastasis on the left side. Bone metastases in C3, T3,4,7.

November 28, 2023: CT guided tumor biopsy: Histology confirmed lung adenocarcinoma. Molecular panel sequencing revealed mutations: EGFR p.E746_A750del (AF 43%), TP53 p.A138_Q144del (AF 37%), MET Amplification FISH positive. Tumor purity was 30%. Tumor Mutational Burden (TMB) was 3.8 Mut/MB.

December 5, 2023: Initiated chemotherapy with Carboplatin and Pemetrexed + immunotherapy with Pembrolizumab.

March 10, 2024: Follow-up CT scan: Partial Response. Continued chemotherapy regimen.

March - May 2024: Continued therapy with Carbo/Pem + Pembrolizumab.

May 07, 2024: CT-scan Chest/Abdomen: Significant disease progression. Mass in the left upper lobe has increased to approximately 6.5 cm with further invasion into the left main bronchus and adjacent vascular structures. Enlarged mediastinal lymph nodes are now more prominent, especially in the subcarinal and right paratracheal regions, with the largest node now measuring 2.5 cm. Progressive pleural effusion left > right. Additionally, there are diffuse ground-glass opacities and reticular
markings throughout both lungs, suspicious for immune mediated Pneumonitis.

Abdomen and Pelvis: Multiple liver lesions, with the largest in segment VIII now measuring 4.5 cm and another in segment IVa measuring 3.0 cm. New metastatic lesions observed in segments V and VI. The adrenal metastasis on the left side has increased in size to 2.5 cm.

Bone Metastases: Increased metastatic involvement with new lesions identified in the spine, including C2, T5, and L1, in addition to the previously noted C3, T3, T4, and T7.

May 08, 2024: Started on Prednisone 40 mg daily because of Lung findings.
Follow-up CT scan and pulmonary function tests scheduled.
Patient advised on potential side effects and the need for regular monitoring.

May 10, 2024: Tumor board review recommended considering eligibility for clinical trials due to limited response to standard and investigational therapies.

May 15, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 4,800/mcL, platelet count 220,000/mcL, total bilirubin 0.9 mg/dL, AST/ALT within normal limits, creatinine 0.9 mg/dL, hemoglobin 13.5 g/dL, serum albumin 4.2 g/dL, lipase and amylase within normal limits.

===== Patient 6.1 =====

Patient Information

Name: Ehrich, Wolfgang

born: 18.08.1968

Address: Kurfürstendamm 1, Berlin, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IVA, M1a (contralateral metastases, malignant pleural effusions),

KRAS G12C mutant non-small cell lung cancer (NSCLC)

Initial Detection: March 22, 2023, following symptoms of persistent cough and weight loss

Biopsy Date: April 15, 2023, squamous cell lung cancer, PDL1 3%

Molecular Profile: Molecular alterations: KRAS p.G12C (AF 18%), KRAS p.G12C (AF

18%), KEAP1 p.L276F (AF 45%), STK11 p.K83Tfs*13 (AF 38%).

Therapy Overview

Combined Immuno-chemotherapy: Began May 5, 2023, with Cisplatin,

Pemetrexed and Pembrolizumab, partial response noted after cycle completion by August 10, 2023, continuation of therapy until october 2023 (progressive disease)

Current Status

Health Condition: Stable with an ECOG performance status of 1

Comorbidities

Former Smoker: 40 py

Hypertension Stage I

COPD GOLD 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Medication

Lisinopril 20mg 1-0-0

Metformin 1000mg 1-0-1

Atorvastatin 40mg 0-0-0-1

Tiotropium (Inhaler) on demand

Novalgin 500mg 1–1-1-1

Apixaban 5mg 1-0-1

Chronological Medical Findings:

March 22, 2023: Experienced persistent cough and weight loss. Chest X-ray and CT scan revealed a mass in the left lung. Referred to oncologist. CT-Angiography: Tumor Size: Approximately 4.5 cm in diameter. At least 2 contralateral metastases. Bronchial Obstruction: Partial obstruction of the left main bronchus leading to atelectasis of the left upper lobe. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Thrombus in the left atrium at the transition to the auricle. Emphysematous and fibrotic changes in the lung parenchyma. Urgent suspicion of a tumor-atelectasis complex in the left upper lobe of the lung. Mucus present in the lower lobe bronchi on the left. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum, particularly in regions 4R and infracarinal.

April 15, 2023: Lung biopsy via bronchoscopy: Endobronchial tumor manifestation in the distal left main bronchus extending to the upper lobe. Acute and chronic atrophic tracheobronchitis. Collapsed bronchial system in the affected area. Biopsy taken. Diagnosed with squamous non-small cell lung cancer (NSCLC), molecular diagnostics: KRAS G12C mutant.

April 27, 2023: Ventilation: Moderate obstruction, no restriction. Increased airway resistance and slight hyperinflation. Tiffeneau index (FEV1/FVC) at 42.34%, z-score -3.32. FEV1: 0.93 L (42% predicted), z-score -2.89.Total lung capacity (TLC): 5.86 L (103% predicted), z-score 0.22. Forced vital capacity (FVC): 2.19 L, z-score -1.5. Residual volume (RV): 3.67 L, z-score 2.44. RV/TLC: 62.68%, z-score -1.18.

May 5, 2023: Initiated on platinum-based immunochemotherapy regimen (Cisplatin, Pemetrexed, Pembrolizumab).

August 10, 2023: Completed initial therapy cycle. Partial response as per CT chest / abdomen +PET CT:  Moderate reduction in tumor size to approximately 4.2 cm. Contralateral metastases still present, but no new lesions. Partial bronchial obstruction persists with ongoing atelectasis in the left upper lobe. Mediastinal lymph nodes remain enlarged and FDG-positive, although with reduced metabolic activity. Thrombus in the left atrium remains unchanged. Emphysematous and fibrotic changes are stable. Overall, mild response observed with no significant progression, as per RECIST stable disease.

August-October: Continued chemotherapy with Cisplatin/Pemetrexed and Pembrolizumab.

October 13, 2023: Follow-up CT (chest + abdomen): SD / Progressive Disease. New nodule in the right lung (1cm). Slight increase in the size of previously noted FDG-positive lymph nodes in the mediastinum. No additional metastatic lesions were detected. The patient has continued to tolerate the current treatment regimen well, with no significant adverse effects reported.

October 17, 2023: Tumor board: SD. Continuation of therapy.

October 25, 2023: Continuation of Cisplatin (dose reduced), Pemetrexed and Pembrolizumab.

January 12, 2024: Follow-up CT scan abdomen and chest, FDG-PET-CT: Progressive Disease with three new metastases in the right lung and additional enlarged FDG-positive lymph nodes in the mediastinum. MRI scan of the brain conducted; no evidence of metastatic disease. Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities consistent with chronic microvascular ischemic changes.

March 17, 2024: Tumorboard recommends considering clinical trial options due to limited response to standard therapies.

April 20, 2024: Detailed assessment of health status. ECOG performance status 1. All routine labs, including liver and renal function tests, within normal limits.

===== Patient 6.1.1 =====

Patient Information

Name: Ehrich, Wolfgang

born: 18.08.1968

Address: Kurfürstendamm 1, Berlin, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IVA, M1a (contralateral metastases, malignant pleural effusions),

KRAS G12C mutant non-small cell lung cancer (NSCLC)

Initial Detection: March 22, 2023, following symptoms of persistent cough and weight loss

Biopsy Date: April 15, 2023, squamous cell lung cancer, PDL1 3%

Molecular Profile: Molecular alterations: KRAS p.G12C (AF 18%), KRAS p.G12C (AF

18%), KEAP1 p.L276F (AF 45%), STK11 p.K83Tfs*13 (AF 38%).

Therapy Overview

Combined Immuno-chemotherapy: Began May 5, 2023, with Cisplatin,

Pemetrexed and Pembrolizumab, partial response noted after cycle completion by August 10, 2023, continuation of therapy until october 2023 (progressive disease)

Current Status

Health Condition: Stable with an ECOG performance status of 1

Comorbidities

Chronic heart failure (NYHA Class III),
reduced ejection fraction (HFrEF) of 35%

Post Myocardial Infarction (2021), 2 coronary stents

Former Smoker: 40 py

Hypertension Stage I

COPD GOLD 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Medication

Lisinopril 20mg 1-0-0

Metformin 1000mg 1-0-1

ASS 100mg 1-0-0

Carvedilol 12.5mg 1-0-1

Furosemide 40mg 1-0-1

Apixaban 5mg 1-0-1

Atorvastatin 40mg 0-0-0-1

Tiotropium (Inhaler) on demand

Novalgin 500mg 1-1-1-1

Chronological Medical Findings:

March 22, 2023: Experienced persistent cough and weight loss. Chest X-ray and CT scan revealed a mass in the left lung. Referred to oncologist. CT-Angiography: Tumor Size: Approximately 4.5 cm in diameter. At least 2 contralateral metastases. Bronchial Obstruction: Partial obstruction of the left main bronchus leading to atelectasis of the left upper lobe. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Thrombus in the left atrium at the transition to the auricle. Emphysematous and fibrotic changes in the lung parenchyma. Urgent suspicion of a tumor-atelectasis complex in the left upper lobe of the lung. Mucus present in the lower lobe bronchi on the left. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum, particularly in regions 4R and infracarinal.

April 15, 2023: Lung biopsy via bronchoscopy: Endobronchial tumor manifestation in the distal left main bronchus extending to the upper lobe. Acute and chronic atrophic tracheobronchitis. Collapsed bronchial system in the affected area. Biopsy taken. Diagnosed with squamous non-small cell lung cancer (NSCLC), molecular diagnostics: KRAS G12C mutant.

April 27, 2023: Ventilation: Moderate obstruction, no restriction. Increased airway resistance and slight hyperinflation. Tiffeneau index (FEV1/FVC) at 42.34%, z-score -3.32. FEV1: 0.93 L (42% predicted), z-score -2.89.Total lung capacity (TLC): 5.86 L (103% predicted), z-score 0.22. Forced vital capacity (FVC): 2.19 L, z-score -1.5. Residual volume (RV): 3.67 L, z-score 2.44. RV/TLC: 62.68%, z-score -1.18.

May 5, 2023: Initiated on platinum-based immunochemotherapy regimen (Cisplatin, Pemetrexed, Pembrolizumab).

August 10, 2023: Completed initial therapy cycle. Partial response as per CT chest / abdomen +PET CT:  Moderate reduction in tumor size to approximately 4.2 cm. Contralateral metastases still present, but no new lesions. Partial bronchial obstruction persists with ongoing atelectasis in the left upper lobe. Mediastinal lymph nodes remain enlarged and FDG-positive, although with reduced metabolic activity. Thrombus in the left atrium remains unchanged. Emphysematous and fibrotic changes are stable. Overall, mild response observed with no significant progression, as per RECIST stable disease.

August-October: Continued chemotherapy with Cisplatin/Pemetrexed and Pembrolizumab.

October 13, 2023: Follow-up CT (chest + abdomen): SD / Progressive Disease. New nodule in the right lung (1cm). Slight increase in the size of previously noted FDG-positive lymph nodes in the mediastinum. No additional metastatic lesions were detected. The patient has continued to tolerate the current treatment regimen well, with no significant adverse effects reported.

October 17, 2023: Tumor board: SD. Continuation of therapy.

October 25, 2023: Continuation of Cisplatin (dose reduced), Pemetrexed and Pembrolizumab.

January 12, 2024: Follow-up CT scan abdomen and chest, FDG-PET-CT: Progressive Disease with three new metastases in the right lung and additional enlarged FDG-positive lymph nodes in the mediastinum. MRI scan of the brain revealed multiple metastases,
specifically three lesions in the left hemisphere:
one in the left frontal lobe, one in the left parietal lobe,
and one in the left occipital lobe. Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities consistent with chronic microvascular ischemic changes.

March 17, 2024: Tumorboard recommends considering clinical trial options due to limited response to standard therapies.

April 20, 2024: Detailed assessment of health status. Patient currently in ECOG performance status 1. All routine labs, including liver and renal function tests, within normal limits.

===== Patient 6.1.2 =====

Patient Information

Name: Ehrich, Wolfgang

born: 18.08.1968

Address: Kurfürstendamm 1, Berlin, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IVA, M1a (contralateral metastases, malignant pleural effusions),

KRAS G12C mutant non-small cell lung cancer (NSCLC)

Initial Detection: March 22, 2023, following symptoms of persistent cough and weight loss

Biopsy Date: April 15, 2023, squamous cell lung cancer, PDL1 3%

Molecular Profile: Molecular alterations: KRAS p.G12C (AF 18%), KRAS p.G12C (AF

18%), KEAP1 p.L276F (AF 45%), STK11 p.K83Tfs*13 (AF 38%).

Therapy Overview

Combined Immuno-chemotherapy: Began May 5, 2023, with Cisplatin,

Pemetrexed and Pembrolizumab, partial response noted after cycle completion by August 10, 2023, continuation of therapy until october 2023 (progressive disease)

Current Status

Health Condition: Stable with an ECOG performance status of 1

Comorbidities

Chronic heart failure (NYHA Class III), reduced ejection fraction
(HFrEF) of 35%

Post Myocardial Infarction (2021), 2 coronary stents

Former Smoker: 40 py

Hypertension Stage I

COPD GOLD 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Medication

Lisinopril 20mg 1-0-0

Metformin 1000mg 1-0-1

ASS 100mg 1-0-0

Carvedilol 12.5mg 1-0-1

Furosemide 40mg 1-0-1

Apixaban 5mg 1-0-1

Atorvastatin 40mg 0-0-0-1

Tiotropium (Inhaler) on demand

Novalgin 500mg 1-1-1-1

Chronological Medical Findings:

March 22, 2023: Experienced persistent cough and weight loss. Chest X-ray and CT scan revealed a mass in the left lung. Referred to oncologist. CT-Angiography: Tumor Size: Approximately 4.5 cm in diameter. At least 2 contralateral metastases. Bronchial Obstruction: Partial obstruction of the left main bronchus leading to atelectasis of the left upper lobe. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Thrombus in the left atrium at the transition to the auricle. Emphysematous and fibrotic changes in the lung parenchyma. Urgent suspicion of a tumor-atelectasis complex in the left upper lobe of the lung. Mucus present in the lower lobe bronchi on the left. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum, particularly in regions 4R and infracarinal.

April 15, 2023: Lung biopsy via bronchoscopy: Endobronchial tumor manifestation in the distal left main bronchus extending to the upper lobe. Acute and chronic atrophic tracheobronchitis. Collapsed bronchial system in the affected area. Biopsy taken. Diagnosed with squamous non-small cell lung cancer (NSCLC), molecular diagnostics: KRAS G12C mutant.

April 27, 2023: Ventilation: Moderate obstruction, no restriction. Increased airway resistance and slight hyperinflation. Tiffeneau index (FEV1/FVC) at 42.34%, z-score -3.32. FEV1: 0.93 L (42% predicted), z-score -2.89.Total lung capacity (TLC): 5.86 L (103% predicted), z-score 0.22. Forced vital capacity (FVC): 2.19 L, z-score -1.5. Residual volume (RV): 3.67 L, z-score 2.44. RV/TLC: 62.68%, z-score -1.18.

May 5, 2023: Initiated on platinum-based immunochemotherapy regimen (Cisplatin, Pemetrexed, Pembrolizumab).

August 10, 2023: Completed initial therapy cycle. Partial response as per CT chest / abdomen +PET CT:  Moderate reduction in tumor size to approximately 4.2 cm. Contralateral metastases still present, but no new lesions. Partial bronchial obstruction persists with ongoing atelectasis in the left upper lobe. Mediastinal lymph nodes remain enlarged and FDG-positive, although with reduced metabolic activity. Thrombus in the left atrium remains unchanged. Emphysematous and fibrotic changes are stable. Overall, mild response observed with no significant progression, as per RECIST stable disease.

August-October: Continued chemotherapy with Cisplatin/Pemetrexed and Pembrolizumab.

October 13, 2023: Follow-up CT (chest + abdomen): SD / Progressive Disease. New nodule in the right lung (1cm). Slight increase in the size of previously noted FDG-positive lymph nodes in the mediastinum. No additional metastatic lesions were detected. The patient has continued to tolerate the current treatment regimen well, with no significant adverse effects reported.

October 17, 2023: Tumor board: SD. Continuation of therapy.

October 25, 2023: Continuation of Cisplatin (dose reduced), Pemetrexed and Pembrolizumab.

January 12, 2024: Follow-up CT scan abdomen and chest, FDG-PET-CT: Progressive Disease with three new metastases in the right lung and additional enlarged FDG-positive lymph nodes in the mediastinum.
MRI scan of the brain revealed multiple metastases,
specifically three lesions in the left hemisphere:
one in the left frontal lobe,
one in the left parietal lobe, and one in the left occipital lobe. Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities consistent with chronic microvascular ischemic changes.

March 17, 2024: Tumorboard recommends considering clinical trial options due to limited response to standard therapies.

April 20, 2024: Detailed assessment of health status.
Patient currently in ECOG performance status 2.
Routine labs: GOT 103 U/L, GPT 112 U/L, Creatinine 2.3 mg/dL

===== Patient 6.2 =====

Patient Information

Name: Ehrich, Wolfgang

born: 18.08.1968

Address: Kurfürstendamm 1, Berlin, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IVA, M1a (contralateral metastases, malignant pleural effusions),

KRAS G12C mutant non-small cell lung cancer (NSCLC)

Initial Detection: March 22, 2023, following symptoms of persistent cough and weight loss

Biopsy Date: April 15, 2023, squamous cell lung cancer, PDL1 3%

Molecular Profile: Molecular alterations: KRAS p.G12C (AF 18%), KRAS p.G12C (AF

18%), KEAP1 p.L276F (AF 45%), STK11 p.K83Tfs*13 (AF 38%).

Therapy Overview

Combined Immuno-chemotherapy: Began May 5, 2023, with Cisplatin,

Pemetrexed and Pembrolizumab, partial response noted after cycle completion by August 10, 2023, continuation of therapy until october 2023 (progressive disease)

Current Status

Health Condition: Stable with an ECOG performance status of 1

Comorbidities

Former Smoker: 40 py

Hypertension Stage I

COPD GOLD 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Medication

Lisinopril 20mg 1-0-0

Metformin 1000mg 1-0-1

Atorvastatin 40mg 0-0-0-1

Tiotropium (Inhaler) on demand

Novalgin 500mg 1–1-1-1

Apixaban 5mg 1-0-1

Chronological Medical Findings:

March 22, 2023: Experienced persistent cough and weight loss. Chest X-ray and CT scan revealed a mass in the left lung. Referred to oncologist. CT-Angiography: Tumor Size: Approximately 4.5 cm in diameter. At least 2 contralateral metastases. Bronchial Obstruction: Partial obstruction of the left main bronchus leading to atelectasis of the left upper lobe. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Thrombus in the left atrium at the transition to the auricle. Emphysematous and fibrotic changes in the lung parenchyma. Urgent suspicion of a tumor-atelectasis complex in the left upper lobe of the lung. Mucus present in the lower lobe bronchi on the left. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum, particularly in regions 4R and infracarinal.

April 15, 2023: Lung biopsy via bronchoscopy: Endobronchial tumor manifestation in the distal left main bronchus extending to the upper lobe. Acute and chronic atrophic tracheobronchitis. Collapsed bronchial system in the affected area. Biopsy taken. Diagnosed with squamous non-small cell lung cancer (NSCLC), molecular diagnostics: KRAS G12C mutant.

April 27, 2023: Ventilation: Moderate obstruction, no restriction. Increased airway resistance and slight hyperinflation. Tiffeneau index (FEV1/FVC) at 42.34%, z-score -3.32. FEV1: 0.93 L (42% predicted), z-score -2.89.Total lung capacity (TLC): 5.86 L (103% predicted), z-score 0.22. Forced vital capacity (FVC): 2.19 L, z-score -1.5. Residual volume (RV): 3.67 L, z-score 2.44. RV/TLC: 62.68%, z-score -1.18.

May 5, 2023: Initiated on platinum-based immunochemotherapy regimen (Cisplatin, Pemetrexed, Pembrolizumab).

August 10, 2023: Completed initial therapy cycle. Partial response as per CT chest / abdomen +PET CT:  Moderate reduction in tumor size to approximately 4.2 cm. Contralateral metastases still present, but no new lesions. Partial bronchial obstruction persists with ongoing atelectasis in the left upper lobe. Mediastinal lymph nodes remain enlarged and FDG-positive, although with reduced metabolic activity. Thrombus in the left atrium remains unchanged. Emphysematous and fibrotic changes are stable. Overall, mild response observed with no significant progression, as per RECIST stable disease.

August-October: Continued chemotherapy with Cisplatin/Pemetrexed and Pembrolizumab.

October 13, 2023: Follow-up CT (chest + abdomen): SD / Progressive Disease. New nodule in the right lung (1cm). Slight increase in the size of previously noted FDG-positive lymph nodes in the mediastinum. No additional metastatic lesions were detected. The patient has continued to tolerate the current treatment regimen well, with no significant adverse effects reported.

October 17, 2023: Tumor board: SD. Continuation of therapy.

October 25, 2023: Continuation of Cisplatin (dose reduced), Pemetrexed and Pembrolizumab.

January 12, 2024: Follow-up CT scan abdomen and chest, FDG-PET-CT: Progressive Disease with three new metastases in the right lung and additional enlarged FDG-positive lymph nodes in the mediastinum. MRI scan of the brain conducted; no evidence of metastatic disease. Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities consistent with chronic microvascular ischemic changes.

March 17, 2024: Tumorboard recommends considering clinical trial options due to limited response to standard therapies.

April 20, 2024: Detailed assessment of health status. ECOG performance status 1. All routine labs, including liver and renal function tests, within normal limits.

===== Patient 6.2.1 =====

Patient Information

Name: Ehrich, Wolfgang

born: 18.08.1968

Address: Kurfürstendamm 1, Berlin, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IVB, M1c (brain metastases),

KRAS G12C mutant non-small cell lung cancer (NSCLC)

Initial Detection: March 22, 2023, following symptoms of persistent cough and weight loss

Biopsy Date: April 15, 2023, squamous cell lung cancer, PDL1 3%

Molecular Profile: Molecular alterations: KRAS p.G12C (AF 18%), KRAS p.G12C (AF

18%), KEAP1 p.L276F (AF 45%), STK11 p.K83Tfs*13 (AF 38%).

Therapy Overview

Combined Immuno-chemotherapy: Began May 5, 2023, with Cisplatin,

Pemetrexed and Pembrolizumab, partial response noted after cycle completion by August 10, 2023, continuation of therapy until october 2023 (progressive disease)

Current Status

Health Condition: Stable with an ECOG performance status of 1

Comorbidities

Former Smoker: 40 py

Hypertension Stage I

COPD GOLD 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Medication

Lisinopril 20mg 1-0-0

Metformin 1000mg 1-0-1

Atorvastatin 40mg 0-0-0-1

Tiotropium (Inhaler) on demand

Novalgin 500mg 1–1-1-1

Apixaban 5mg 1-0-1

Chronological Medical Findings:

March 22, 2023: Experienced persistent cough and weight loss. Chest X-ray and CT scan revealed a mass in the left lung. Referred to oncologist. CT-Angiography: Tumor Size: Approximately 4.5 cm in diameter. At least 2 contralateral metastases. Bronchial Obstruction: Partial obstruction of the left main bronchus leading to atelectasis of the left upper lobe. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Thrombus in the left atrium at the transition to the auricle. Emphysematous and fibrotic changes in the lung parenchyma. Urgent suspicion of a tumor-atelectasis complex in the left upper lobe of the lung. Mucus present in the lower lobe bronchi on the left. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum, particularly in regions 4R and infracarinal.

April 15, 2023: Lung biopsy via bronchoscopy: Endobronchial tumor manifestation in the distal left main bronchus extending to the upper lobe. Acute and chronic atrophic tracheobronchitis. Collapsed bronchial system in the affected area. Biopsy taken. Diagnosed with squamous non-small cell lung cancer (NSCLC), molecular diagnostics: KRAS G12C mutant.

April 27, 2023: Ventilation: Moderate obstruction, no restriction. Increased airway resistance and slight hyperinflation. Tiffeneau index (FEV1/FVC) at 42.34%, z-score -3.32. FEV1: 0.93 L (42% predicted), z-score -2.89.Total lung capacity (TLC): 5.86 L (103% predicted), z-score 0.22. Forced vital capacity (FVC): 2.19 L, z-score -1.5. Residual volume (RV): 3.67 L, z-score 2.44. RV/TLC: 62.68%, z-score -1.18.

May 5, 2023: Initiated on platinum-based immunochemotherapy regimen (Cisplatin, Pemetrexed, Pembrolizumab).

August 10, 2023: Completed initial therapy cycle. Partial response as per CT chest / abdomen +PET CT:  Moderate reduction in tumor size to approximately 4.2 cm. Contralateral metastases still present, but no new lesions. Partial bronchial obstruction persists with ongoing atelectasis in the left upper lobe. Mediastinal lymph nodes remain enlarged and FDG-positive, although with reduced metabolic activity. Thrombus in the left atrium remains unchanged. Emphysematous and fibrotic changes are stable. Overall, mild response observed with no significant progression, as per RECIST stable disease.

August-October: Continued chemotherapy with Cisplatin/Pemetrexed and Pembrolizumab.

October 13, 2023: Follow-up CT (chest + abdomen): SD / Progressive Disease. New nodule in the right lung (1cm). Slight increase in the size of previously noted FDG-positive lymph nodes in the mediastinum. No additional metastatic lesions were detected. The patient has continued to tolerate the current treatment regimen well, with no significant adverse effects reported.

October 17, 2023: Tumor board: SD. Continuation of therapy.

October 25, 2023: Continuation of Cisplatin (dose reduced), Pemetrexed and Pembrolizumab.

January 12, 2024: Follow-up CT scan abdomen and chest, FDG-PET-CT: Progressive Disease with three new metastases in the right lung and additional enlarged FDG-positive lymph nodes in the mediastinum. MRI scan of the brain: MRI scan of the brain revealed multiple
metastases, specifically three lesions in the left hemisphere:
one in the left frontal lobe,
one in the left parietal lobe, and one in the left occipital lobe.

January 16, 2024: Begin Sotorasib (Lumakras) 960 per day

March 17, 2024: Tumorboard recommends considering clinical trial options due to limited response to standard therapies.

April 20, 2024: Detailed assessment of health status. ECOG performance status 1. All routine labs, including liver and renal function tests, within normal limits.

===== Patient 6.3 =====

Patient Information

Name: Ehrich, Wolfgang

born: 18.08.1968

Address: Italy

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IVA, M1a (contralateral metastases),

KRAS G12C mutant non-small cell lung cancer (NSCLC) / adenocarcinoma of the

lung

Initial Detection: March 22, 2024, following symptoms of persistent cough and weight loss (-5kg)

Biopsy Date: April 15, 2024, adenocarcinoma, PDL1 3%

Molecular Profile: Molecular alterations: KRAS p.G12C (AF 18%), KRAS p.G12C (AF

18%), KEAP1 p.L276F (AF 45%), STK11 p.K83Tfs*13 (AF 38%).

Therapy Overview

None.

Current Status

Health Condition: Stable with an ECOG performance status of 1

Allergies: None.

Comorbidities

Former Smoker: 40 py

Hypertension Stage I

COPD GOLD 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Medication

Lisinopril 20mg 1-0-0

Metformin 1000mg 1-0-1

Atorvastatin 40mg 0-0-0-1

Tiotropium (Inhaler) on demand

Novalgin 500mg 1–1-1-1

Apixaban 5mg 1-0-1

Chronological Medical Findings:

March 22, 2024: Experienced persistent cough and weight loss. Chest X-ray and CT scan revealed a mass in the left lung. Referred to oncologist. CT-Angiography: Tumor Size: Approximately 4.5 cm in diameter. At least 2 contralateral metastases. Bronchial Obstruction: Partial obstruction of the left main bronchus leading to atelectasis of the left upper lobe. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Thrombus in the left atrium at the transition to the auricle. Emphysematous and fibrotic changes in the lung parenchyma. Urgent suspicion of a tumor-atelectasis complex in the left upper lobe of the lung. Mucus present in the lower lobe bronchi on the left. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum, particularly in regions 4R and infracarinal.

April 15, 2024: Lung biopsy via bronchoscopy: Endobronchial tumor manifestation in the distal left main bronchus extending to the upper lobe. Acute and chronic atrophic tracheobronchitis. Collapsed bronchial system in the affected area. Biopsy taken. Diagnosed with non-small cell lung cancer (NSCLC) (adenocarcinoma), molecular diagnostics: KRAS G12C mutant.

April 27, 2024: Ventilation: Moderate obstruction, no restriction. Increased airway resistance and slight hyperinflation. Tiffeneau index (FEV1/FVC) at 42.34%, z-score -3.32. FEV1: 0.93 L (42% predicted), z-score -2.89.Total lung capacity (TLC): 5.86 L (103% predicted), z-score 0.22. Forced vital capacity (FVC): 2.19 L, z-score -1.5. Residual volume (RV): 3.67 L, z-score 2.44. RV/TLC: 62.68%, z-score -1.18.

April 20, 2024: Detailed assessment of health status. ECOG performance status 1. All routine labs, including liver and renal function tests, within normal limits. Discussion in tumor board conference: palliative systemic treatment or clinical trial enrollment.

===== Patient 6.3.1 =====

Patient Information

Name: Ehrich, Wolfgang

born: 18.08.1968

Address: Italy

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IVA, M1a (contralateral metastases, pleural effusions),

KRAS G12C mutant non-small cell lung cancer (NSCLC) / adenocarcinoma of the

lung

Initial Detection: March 22, 2024, following symptoms of persistent cough and weight loss (-5kg)

Biopsy Date: April 15, 2024, adenocarcinoma, PDL1 3%

Molecular Profile: Molecular alterations: KRAS p.G12C (AF 18%), KRAS p.G12C (AF

18%), KEAP1 p.L276F (AF 45%), STK11 p.K83Tfs*13 (AF 38%).

Therapy Overview

None.

Current Status

Health Condition: Stable with an ECOG performance status of 1

Allergies: None.

Comorbidities

Former Smoker: 40 py

Hypertension Stage I

COPD GOLD 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Medication

Lisinopril 20mg 1-0-0

Metformin 1000mg 1-0-1

Atorvastatin 40mg 0-0-0-1

Tiotropium (Inhaler) on demand

Novalgin 500mg 1–1-1-1

Apixaban 5mg 1-0-1

Chronological Medical Findings:

March 22, 2024: Experienced persistent cough and weight loss. Chest X-ray and CT scan revealed a mass in the left lung. Referred to oncologist. CT-Angiography: Tumor Size: Approximately 4.5 cm in diameter. At least 2 contralateral metastases. Bronchial Obstruction: Partial obstruction of the left main bronchus leading to atelectasis of the left upper lobe. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Thrombus in the left atrium at the transition to the auricle. Emphysematous and fibrotic changes in the lung parenchyma. Urgent suspicion of a tumor-atelectasis complex in the left upper lobe of the lung. Mucus present in the lower lobe bronchi on the left. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum, particularly in regions 4R and infracarinal. Bilateral pleural effusions, additionally mild pericardial effusion.

April 15, 2024: Lung biopsy via bronchoscopy: Endobronchial tumor manifestation in the distal left main bronchus extending to the upper lobe. Acute and chronic atrophic tracheobronchitis. Collapsed bronchial system in the affected area. Biopsy taken. Diagnosed with non-small cell lung cancer (NSCLC) (adenocarcinoma), molecular diagnostics: KRAS G12C mutant.

April 27, 2024: Ventilation: Moderate obstruction, no restriction. Increased airway resistance and slight hyperinflation. Tiffeneau index (FEV1/FVC) at 42.34%, z-score -3.32. FEV1: 0.93 L (42% predicted), z-score -2.89.Total lung capacity (TLC): 5.86 L (103% predicted), z-score 0.22. Forced vital capacity (FVC): 2.19 L, z-score -1.5. Residual volume (RV): 3.67 L, z-score 2.44. RV/TLC: 62.68%, z-score -1.18.

April 20, 2024: Detailed assessment of health status.
ECOG performance status 2. All routine labs, including liver and renal function tests, within normal limits. Discussion in tumor board conference: palliative systemic treatment or clinical trial enrollment.

===== Patient 6.4 =====

Patient Information

Name: Ehrich, Wolfgang

born: 18.08.1968

Address: Kurfürstendamm 1, Berlin, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IVA, M1a (contralateral metastases, malignant pleural effusions),

KRAS G12C mutant non-small cell lung cancer (NSCLC)

Initial Detection: March 22, 2023, following symptoms of persistent cough and weight loss

Biopsy Date: April 15, 2023, squamous cell lung cancer, PDL1 3%

Molecular Profile: Molecular alterations: KRAS p.G12C (AF 18%), KRAS p.G12C (AF

18%), KEAP1 p.L276F (AF 45%), STK11 p.K83Tfs*13 (AF 38%).

Therapy Overview

Combined Immuno-chemotherapy: Began May 5, 2023, with Cisplatin,

Pemetrexed and Pembrolizumab, partial response noted after cycle completion by August 10, 2023, continuation of therapy until october 2023 (progressive disease)

Current Status

Health Condition: Stable with an ECOG performance status of 1

Comorbidities

Former Smoker: 40 py

Hypertension Stage I

COPD GOLD 2

Type 2 Diabetes Mellitus

Hyperlipidemia

Medication

Lisinopril 20mg 1-0-0

Metformin 1000mg 1-0-1

Atorvastatin 40mg 0-0-0-1

Tiotropium (Inhaler) on demand

Novalgin 500mg 1–1-1-1

Apixaban 5mg 1-0-1

Chronological Medical Findings:

March 22, 2023: Experienced persistent cough and weight loss. Chest X-ray and CT scan revealed a mass in the left lung. Referred to oncologist. CT-Angiography: Tumor Size: Approximately 4.5 cm in diameter. At least 2 contralateral metastases. Bronchial Obstruction: Partial obstruction of the left main bronchus leading to atelectasis of the left upper lobe. Suspicion of mediastinal lymph node metastases. No evidence of pulmonary artery embolism. Thrombus in the left atrium at the transition to the auricle. Emphysematous and fibrotic changes in the lung parenchyma. Urgent suspicion of a tumor-atelectasis complex in the left upper lobe of the lung. Mucus present in the lower lobe bronchi on the left. Lymph Nodes: Enlarged, FDG-positive lymph nodes in the mediastinum, particularly in regions 4R and infracarinal.

April 15, 2023: Lung biopsy via bronchoscopy: Endobronchial tumor manifestation in the distal left main bronchus extending to the upper lobe. Acute and chronic atrophic tracheobronchitis. Collapsed bronchial system in the affected area. Biopsy taken. Diagnosed with squamous non-small cell lung cancer (NSCLC), molecular diagnostics: KRAS G12C mutant.

April 27, 2023: Ventilation: Moderate obstruction, no restriction. Increased airway resistance and slight hyperinflation. Tiffeneau index (FEV1/FVC) at 42.34%, z-score -3.32. FEV1: 0.93 L (42% predicted), z-score -2.89.Total lung capacity (TLC): 5.86 L (103% predicted), z-score 0.22. Forced vital capacity (FVC): 2.19 L, z-score -1.5. Residual volume (RV): 3.67 L, z-score 2.44. RV/TLC: 62.68%, z-score -1.18.

May 5, 2023: Initiated on platinum-based immunochemotherapy regimen (Cisplatin, Pemetrexed, Pembrolizumab).

August 10, 2023: Completed initial therapy cycle. Partial response as per CT chest / abdomen +PET CT:  Moderate reduction in tumor size to approximately 4.2 cm. Contralateral metastases still present, but no new lesions. Partial bronchial obstruction persists with ongoing atelectasis in the left upper lobe. Mediastinal lymph nodes remain enlarged and FDG-positive, although with reduced metabolic activity. Thrombus in the left atrium remains unchanged. Emphysematous and fibrotic changes are stable. Overall, mild response observed with no significant progression, as per RECIST stable disease.

August-October: Continued chemotherapy with Cisplatin/Pemetrexed and Pembrolizumab.

October 13, 2023: Follow-up CT (chest + abdomen): SD / Progressive Disease. New nodule in the right lung (1cm). Slight increase in the size of previously noted FDG-positive lymph nodes in the mediastinum. No additional metastatic lesions were detected. The patient has continued to tolerate the current treatment regimen well, with no significant adverse effects reported.

October 17, 2023: Tumor board: SD. Continuation of therapy.

October 25, 2023: Continuation of Cisplatin (dose reduced), Pemetrexed and Pembrolizumab.

January 12, 2024: Follow-up CT scan abdomen and chest, FDG-PET-CT: Progressive Disease with three new metastases in the right lung and additional enlarged FDG-positive lymph nodes in the mediastinum. Primary tumor 5.1 cm in diameter. MRI scan of the brain conducted; no evidence of metastatic disease. Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities consistent with chronic microvascular ischemic changes.

March 17, 2024: Tumorboard recommends considering clinical trial options due to limited response to standard therapies.

April 20, 2024: Detailed assessment of health status. ECOG performance status 1. All routine labs, including liver and renal function tests, within normal limits.

===== Patient 7.1 =====

Patient Information
Name: Jessica Smith
Born: August 10, 1982
Address: Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: UICC Stage IV metastatic malignant melanoma (hepatic, M. pectoralis major)

Initial Detection: January 5, 2024, following a rapidly growing mole and enlarged lymph nodes
Biopsy Date: January 15, 2024
Molecular Profile: Tumor Purity: 80%; Tumor Mutational Burden (TMB): 12.8 Mut/Mb; NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%)

Therapy Overview
Initial Treatment: None so far.

Health Condition: ECOG 1

Comorbidities

Former smoker 10 py

Hypertension Stage 1

Mild Asthma

H/o appendectomy 2014

Medication

Amlodipine 10mg 1-0-0

Albuterol inhaler as needed

Chronological Medical Findings:

January 5, 2024: Presented with a rapidly growing mole on the left arm and enlarged lymph nodes in the axillary region.

January 10, 2024: CT scan of the chest and abdomen: Solid tumor in the left axillary region measuring approximately 3.5 cm with evidence of local invasion into surrounding soft tissues and possibly the pectoralis major muscle. Demonstrates irregular borders and heterogeneous enhancement. Multiple hypodense lesions noted throughout the liver, suggestive of metastatic disease. The largest lesion is located in segment VIII, measuring approximately 2.8 cm in diameter. Additional smaller lesions scattered in both hepatic lobes.

January 15, 2024: Biopsy of the left axillary mass performed. Histology confirmed melanoma. Molecular panel sequencing: NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%). Tumor purity 80%. Tumor Mutational Burden (TMB) 12.8 Mut/Mb.

January 16, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 5,300/mcL, platelet count 140,000/mcL, total bilirubin 1.1 mg/dL, AST/ALT within range, creatinine 1.1 mg/dL, hemoglobin 10.5 g/dL, serum albumin 3.4 g/dL, lipase and amylase within normal limits.

===== Patient 7.1.1 =====

Patient Information
Name: Jessica Smith
Born: August 10, 1982
Address: Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: UICC Stage IV metastatic malignant melanoma (HEP, M. pectoralis major)

Initial Detection: January 5, 2024, following a rapidly growing mole and enlarged lymph nodes
Biopsy Date: January 15, 2024
Molecular Profile: Tumor Purity: 80%; Tumor Mutational Burden (TMB): 12.8 Mut/Mb; NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%)

Therapy Overview
Initial Treatment:
Immunotherapy: Began February 1, 2024, with Nivolumab and Ipilimumab,
partial response noted
after the initial treatment cycle completed by May 15, 2024.
Continued Nivolumab maintenance until December 2024 (progressive disease).

Current Status: Disease progression as of December 2024,
with new metastatic lesions identified.
Health Condition: ECOG 1

Comorbidities

Former smoker 10 py

Hypertension Stage 1

Mild Asthma

H/o appendectomy 2014

Medication

Amlodipine 10mg 1-0-0

Albuterol inhaler as needed

Chronological Medical Findings:

January 5, 2023: Presented with a rapidly growing mole on the left arm and enlarged lymph nodes in the axillary region.

January 10, 2023: CT scan of the chest and abdomen: Solid tumor in the left axillary region measuring approximately 3.5 cm with evidence of local invasion into surrounding soft tissues and possibly the pectoralis major muscle. Demonstrates irregular borders and heterogeneous enhancement. Multiple hypodense lesions noted throughout the liver, suggestive of metastatic disease. The largest lesion is located in segment VIII, measuring approximately 2.8 cm in diameter. Additional smaller lesions scattered in both hepatic lobes.

January 15, 2023: Biopsy of the left axillary mass performed. Histology confirmed melanoma. Molecular panel sequencing: NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%). Tumor purity 80%. Tumor Mutational Burden (TMB) 12.8 Mut/Mb.

February 1, 2023: Initiated combined immunotherapy with Nivolumab and
Ipilimumab.

May 5, 2023: CT scan showed partial response with a decrease in the size of
the primary tumor
and axillary lymph nodes. Partial response also regarding liver mets.
Continued maintenance therapy with Nivolumab.

September 15, 2023: Follow-up imaging: SD.

September - December 2023: Continuation of Nivolumab.

December 18, 2023: Follow-up CT scan: Disease progression with new
metastatic lesions in the liver and bones.
Multiple enlarged lymph nodes persistent in the left axillary region,
consistent with known metastatic melanoma.
No significant change in size or number compared to the previous scan.
Liver demonstrates multiple hypodense lesions throughout both hepatic lobes.
The large lesion located in segment VIII now measures approximately
5.0 cm in diameter.
Previously noted lesions have increased in size, with the largest lesion in segment
IVa now measuring 4.2 cm (previously 3.1 cm).
New lytic lesions are identified in the thoracic spine,
specifically at T5 and T8 vertebral bodies, suggestive of metastatic disease.

December 21, 2023: Bone scan confirmed multiple metastatic lesions in the
thoracic spine.

January 4, 2024: Tumor board review recommended considering eligibility for
clinical trials due to limited response to standard and investigational therapies.

January 16, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 5,300/mcL, platelet count 140,000/mcL, total bilirubin 1.1 mg/dL, AST/ALT within range, creatinine 1.1 mg/dL, hemoglobin 10.5 g/dL, serum albumin 3.4 g/dL, lipase and amylase within normal limits.

===== Patient 7.1.2 =====

Patient Information
Name: Jessica Smith
Born: August 10, 1982
Address: Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: UICC Stage IV metastatic malignant melanoma (hepatic, M. pectoralis major, Bone)

Initial Detection: January 5, 2024, following a rapidly growing mole and enlarged lymph nodes
Biopsy Date: January 15, 2024
Molecular Profile: Tumor Purity: 80%; Tumor Mutational Burden (TMB): 12.8 Mut/Mb; NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%)

Therapy Overview
Initial Treatment: None so far.

Health Condition: ECOG 1

Comorbidities

Former smoker 10 py

Hypertension Stage 1

Mild Asthma

H/o appendectomy 2014

Systemic Lupus Erythematosus (SLE) diagnosed in 2022,
presenting with joint pain, fatigue, and a malar rash

Medication

Hydroxychloroquine 200 mg, once daily Prednisone 5 mg, once daily

Amlodipine 10mg 1-0-0

Albuterol inhaler as needed

Chronological Medical Findings:

January 5, 2024: Presented with a rapidly growing mole on the left arm and enlarged lymph nodes in the axillary region.

January 10, 2024: CT scan of the chest and abdomen: Solid tumor in the left axillary region measuring approximately 3.5 cm with evidence of local invasion into surrounding soft tissues and possibly the pectoralis major muscle. Demonstrates irregular borders and heterogeneous enhancement. Multiple hypodense lesions noted throughout the liver, suggestive of metastatic disease. The largest lesion is located in segment VIII, measuring approximately 2.8 cm in diameter. Additional smaller lesions scattered in both hepatic lobes.

January 15, 2024: Biopsy of the left axillary mass performed. Histology confirmed melanoma. Molecular panel sequencing: NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%). Tumor purity 80%. Tumor Mutational Burden (TMB) 12.8 Mut/Mb.

January 16, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 5,300/mcL, platelet count 140,000/mcL, total bilirubin 1.1 mg/dL, AST/ALT within range, creatinine 1.1 mg/dL, hemoglobin 10.5 g/dL, serum albumin 3.4 g/dL, lipase and amylase within normal limits.

===== Patient 7.1.3 =====

Patient Information
Name: Jessica Smith
Born: August 10, 1982
Address: Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: UICC Stage IV metastatic malignant melanoma (hepatic, M. pectoralis major, brain)

Initial Detection: January 5, 2024, following a rapidly growing mole and enlarged lymph nodes
Biopsy Date: January 15, 2024
Molecular Profile: Tumor Purity: 80%; Tumor Mutational Burden (TMB): 12.8 Mut/Mb; NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%)

Therapy Overview
Initial Treatment: None so far.

Health Condition: ECOG 1

Comorbidities

Former smoker 10 py

Hypertension Stage 1

Mild Asthma

H/o appendectomy 2014

Systemic Lupus Erythematosus (SLE) diagnosed in 2022,
presenting with joint pain, fatigue, and a malar rash

Medication

Hydroxychloroquine 200 mg, once daily Prednisone 5 mg, once daily

Amlodipine 10mg 1-0-0

Albuterol inhaler as needed

Chronological Medical Findings:

January 5, 2024: Presented with a rapidly growing mole on the left arm and enlarged lymph nodes in the axillary region.

January 10, 2024: CT scan of the chest and abdomen: Solid tumor in the left axillary region measuring approximately 3.5 cm with evidence of local invasion into surrounding soft tissues and possibly the pectoralis major muscle. Demonstrates irregular borders and heterogeneous enhancement. Multiple hypodense lesions noted throughout the liver, suggestive of metastatic disease. The largest lesion is located in segment VIII, measuring approximately 2.8 cm in diameter. Additional smaller lesions scattered in both hepatic lobes.

cMRI: Imaging reveals five small brain metastases:
A 1.2 cm lesion in the right frontal lobe.
A 0.8 cm lesion in the left parietal lobe. A 0.6 cm lesion in the right occipital lobe.
A 0.7 cm lesion in the left cerebellum. A 0.9 cm lesion in the right temporal lobe.
All lesions with heterogeneous enhancement and associated with surrounding
vasogenic edema.
No evidence of midline shift or significant mass effect at this time.

January 15, 2024: Biopsy of the left axillary mass performed. Histology confirmed melanoma. Molecular panel sequencing: NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%). Tumor purity 80%. Tumor Mutational Burden (TMB) 12.8 Mut/Mb.

January 16, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 5,300/mcL, platelet count 140,000/mcL, total bilirubin 1.1 mg/dL, AST/ALT within range, creatinine 1.1 mg/dL, hemoglobin 10.5 g/dL, serum albumin 3.4 g/dL, lipase and amylase within normal limits.

===== Patient 7.2 =====

Patient Information

Name: Jessica Smith

Born: August 10, 1982

Address: Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IV metastatic malignant melanoma (hepatic, M. pectoralis major)

Initial Detection: January 5, 2024, following a rapidly growing mole and enlarged lymph nodes

Biopsy Date: January 15, 2024

Molecular Profile: Tumor Purity: 80%; Tumor Mutational Burden (TMB): 12.8 Mut/Mb; NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%)

Therapy Overview

Initial Treatment: None so far.

Health Condition: ECOG 1

Comorbidities

Former smoker 10 py

Hypertension Stage 1

Mild Asthma

H/o appendectomy 2014

Medication

Amlodipine 10mg 1-0-0

Albuterol inhaler as needed

Chronological Medical Findings:

January 5, 2024: Presented with a rapidly growing mole on the left arm and enlarged lymph nodes in the axillary region.

January 10, 2024: CT scan of the chest and abdomen: Solid tumor in the left axillary region measuring approximately 3.5 cm with evidence of local invasion into surrounding soft tissues and possibly the pectoralis major muscle. Demonstrates irregular borders and heterogeneous enhancement. Multiple hypodense lesions noted throughout the liver, suggestive of metastatic disease. The largest lesion is located in segment VIII, measuring approximately 2.8 cm in diameter. Additional smaller lesions scattered in both hepatic lobes.

January 15, 2024: Biopsy of the left axillary mass performed. Histology confirmed melanoma. Molecular panel sequencing: NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%). Tumor purity 80%. Tumor Mutational Burden (TMB) 12.8 Mut/Mb.

January 16, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 5,300/mcL, platelet count 140,000/mcL, total bilirubin 1.1 mg/dL, AST/ALT within range, creatinine 1.1 mg/dL, hemoglobin 10.5 g/dL, serum albumin 3.4 g/dL, lipase and amylase within normal limits.

===== Patient 7.2.1 =====

Patient Information
Name: Jessica Smith
Born: August 10, 1982
Address: Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis
Diagnosis: UICC Stage IV metastatic malignant melanoma (hepatic, M. pectoralis major, brain)

Initial Detection: January 5, 2024, following a rapidly growing mole and enlarged lymph nodes
Biopsy Date: January 15, 2024
Molecular Profile: Tumor Purity: 80%; Tumor Mutational Burden (TMB): 12.8 Mut/Mb; NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%)

Therapy Overview
Initial Treatment: None so far.

Health Condition: ECOG 1

Comorbidities

Former smoker 10 py

Hypertension Stage 1

Mild Asthma

H/o appendectomy 2014

Systemic Lupus Erythematosus (SLE) diagnosed in 2022,
presenting with joint pain, fatigue, and a malar rash

Medication

Hydroxychloroquine 200 mg, once daily Prednisone 5 mg, once daily

Amlodipine 10mg 1-0-0

Albuterol inhaler as needed

Chronological Medical Findings:

January 5, 2024: Presented with a rapidly growing mole on the left arm and enlarged lymph nodes in the axillary region.

January 10, 2024: CT scan of the chest and abdomen: Solid tumor in the left axillary region measuring approximately 3.5 cm with evidence of local invasion into surrounding soft tissues and possibly the pectoralis major muscle. Demonstrates irregular borders and heterogeneous enhancement. Multiple hypodense lesions noted throughout the liver, suggestive of metastatic disease. The largest lesion is located in segment VIII, measuring approximately 2.8 cm in diameter. Additional smaller lesions scattered in both hepatic lobes.

cMRI: Imaging reveals five small brain metastases:
A 1.2 cm lesion in the right frontal lobe.
A 0.8 cm lesion in the left parietal lobe. A 0.6 cm lesion in the right occipital lobe.
A 0.7 cm lesion in the left cerebellum. A 0.9 cm lesion in the right temporal lobe.
All lesions with heterogeneous enhancement and associated with surrounding
vasogenic edema.
No evidence of midline shift or significant mass effect at this time.

January 15, 2024: Biopsy of the left axillary mass performed. Histology confirmed melanoma. Molecular panel sequencing: NF1 p.I1605fs (AF 39%), TP53 c.672+1G>A (AF 50%), RB1 p.Q846* (AF 20%), TERT p.R859Q (AF 41%). Tumor purity 80%. Tumor Mutational Burden (TMB) 12.8 Mut/Mb.

January 16, 2024: Detailed assessment of health status confirmed adequate organ function. Routine labs within normal limits: ANC 5,300/mcL, platelet count 140,000/mcL, total bilirubin 1.1 mg/dL, AST/ALT within range, creatinine 1.1 mg/dL, hemoglobin 10.5 g/dL, serum albumin 3.4 g/dL, lipase and amylase within normal limits.

===== Patient 8.1 =====

Name: Müller, David
Born: 22.03.1970
Address: Hauptstraße 1, Heidelberg, Germany

Overview of Tumor Diagnosis and Therapy
Tumor Diagnosis
Diagnosis: UICC Stage IV FGFR2 mutant intrahepatic cholangiocarcinoma, peritoneal carcinomatosis
Initial Detection: March 5 2022, following symptoms of jaundice and abdominal pain
Molecular Profile:  Panel (Tumor purity 80%), TMB 1.2 Mut/Mb. Molecular alterations: FGFR2::BICC1 Fusion, TP53 p.E258* (AF 52%).

Therapy Overview
Initial Treatment:

Right hemihepatectomy with additional lymphadenectomy June 10, 2023. Histopathology: iCCA, T1b, N1, R0 resection.
Adjuvant chemotherapy: Began June 20, 2023, with Capecitabine. Follow-up CT September 2023 shows multiple new liver lesions and peritoneal metastasis.

Subsequent Treatment:

September - December 2023: 6 cycles Gemzar/Cisplatin + Durvalumab.
January - March 2024: Second line chemotherapy with FOLFOX.

Current Status: ECOG 1

Comorbidities
Hypothyroidism

Medication

Levothyroxine 75µg 1-0-0

Chronological Medical Findings:
February 1, 2023: Complaint of jaundice and abdominal pain. Ultrasound revealed a mass in the liver. Weight loss of -15kg/5 months.

March 5, 2023: MRI of the abdomen: Significant mass measuring approximately 5.5 cm in the right hepatic lobe, consistent with intrahepatic cholangiocarcinoma. Lesion with irregular borders and heterogeneous enhancement patterns. Evidence of bile duct dilation proximal to the mass, suggestive of obstructive cholestasis. Additionally, several enlarged lymph nodes noted in the perihepatic region, displaying increased uptake on FDG-PET, suggestive of potential metastasis. No vascular invasion observed, but the proximity of the mass to the right portal vein concerning for possible future involvement. No signs of distant metastasis present in the visualized organs.

June 10, 2023: Right hemihepatectomy and lymphadenectomy. Histopathology reveals intrahepatic cholangiocarcinoma. pT1b, pN2, pM0, R0. Molecular pathology report: Panel (Tumor purity 80%), TMB 1.2 Mut/Mb. Molecular alterations: FGFR2::BICC1 Fusion, TP53 p.E258* (AF 52%).

June 20, 2023: DPD status normal. Initiated adjuvant chemotherapy with Capecitabine.

September 15, 2023: Follow-up CT (chest + abdomen): Multiple new lesions in the remaining liver tissue, highly suggestive of tumor recurrence. New small nodules in the peritoneum, up to 1 cm, likely peritoneal metastasis. FDG-PET shows elevated activity in hepatic and lymph node lesions. Mild right-sided pleural effusion noted, no significant respiratory compromise.

September 17, 2023: Initiated Therapy with Gemzar/Cisplatin + Durvalumab.

September - December 2023: 6 cycles Gemzar/Cisplatin + Durvalumab.

January 5, 2024: Follow-up MRI scan abdomen/liver: progressive disease (PD) with growth of all liver lesions and increased involvement of adjacent hepatic structures. The peritoneal nodules showed slight growth. Moderate ascites. No evidence of direct vascular invasion, but the tumor's close relationship with the hepatic artery and portal vein concerns potential future involvement. The liver parenchyma shows signs of chronic liver disease, possibly secondary to ongoing cholestasis and tumor-related liver dysfunction.

MRI of the brain was conducted concurrently, revealing no evidence of metastatic disease. Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities, consistent with chronic microvascular ischemic changes.

January - March 2024: Second line chemotherapy with FOLFOX.

March 16, 2024: Progressive disease (PD) with significant growth of all liver lesions. The largest lesion in segment IVb has increased to 7.5 cm in diameter, with invasion into the adjacent hepatic structures. The peritoneal nodules have shown further growth, with the largest nodule now measuring 2.5 cm. Ascites: Moderate to severe ascites is present, with a noticeable increase compared to the previous scan. Vascular Involvement: No direct vascular invasion detected yet, but the lesions now encase the hepatic artery and portal vein, raising significant concerns for potential imminent involvement. Liver Parenchyma: The liver parenchyma shows worsening signs of chronic liver disease, likely secondary to ongoing cholestasis and tumor-related liver dysfunction. Evidence of hepatic decompensation is apparent, with diffuse nodularity and fibrosis indicative of cirrhosis.

Additional Findings: Splenomegaly, consistent with portal hypertension.

January 20, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

January 21, 2024: Patient in good shape, routine lab results within normal ranges. Willing to participate in potential trials.

===== Patient 8.1.1 =====

Name: Müller, David
Born: 22.03.1970
Address: Hauptstraße 1, Heidelberg, Germany

Overview of Tumor Diagnosis and Therapy
Tumor Diagnosis
Diagnosis: UICC Stage IV FGFR2 mutant intrahepatic cholangiocarcinoma, peritoneal carcinomatosis
Initial Detection: March 5 2022, following symptoms of jaundice and abdominal pain
Molecular Profile:  Panel (Tumor purity 80%), TMB 1.2 Mut/Mb. Molecular alterations: FGFR2::BICC1 Fusion, TP53 p.E258* (AF 52%).

Therapy Overview
Initial Treatment:

Right hemihepatectomy with additional lymphadenectomy June 10, 2023. Histopathology: iCCA, T1b, N1, R0 resection.
Adjuvant chemotherapy: Began June 20, 2023, with Capecitabine. Follow-up CT September 2023 shows multiple new liver lesions and peritoneal metastasis.

Subsequent Treatment:

September - December 2023: 6 cycles Gemzar/Cisplatin + Durvalumab.
January - March 2024: Second line chemotherapy with FOLFOX.

Current Status: ECOG 1

Comorbidities
Hypothyroidism

Coronary Artery Disease (CAD)
Status post Myocardial Infarction (MI) on January 10, 2024
ECG January 10, 2024: ST-segment elevation in leads V2-V4,
consistent with anterior wall myocardial infarction.
Reciprocal ST-segment depression in leads II, III, and aVF.
Q waves present in leads V1-V3, indicating myocardial necrosis.
T-wave inversions in leads V2-V4.
QTc time of 485 ms.
Heart rate: 95 bpm. PR interval: 160 ms. QRS duration: 100 ms.

Medication

Levothyroxine 75µg 1-0-0

Ass 100, once daily
Clopidogrel 75 mg, once daily
Atorvastatin 80 mg, once daily
Metoprolol 50 mg, twice daily
Lisinopril 10 mg, once daily

Chronological Medical Findings:
February 1, 2023: Complaint of jaundice and abdominal pain. Ultrasound revealed a mass in the liver. Weight loss of -15kg/5 months.

March 5, 2023: MRI of the abdomen: Significant mass measuring approximately 5.5 cm in the right hepatic lobe, consistent with intrahepatic cholangiocarcinoma. Lesion with irregular borders and heterogeneous enhancement patterns. Evidence of bile duct dilation proximal to the mass, suggestive of obstructive cholestasis. Additionally, several enlarged lymph nodes noted in the perihepatic region, displaying increased uptake on FDG-PET, suggestive of potential metastasis. No vascular invasion observed, but the proximity of the mass to the right portal vein concerning for possible future involvement. No signs of distant metastasis present in the visualized organs.

June 10, 2023: Right hemihepatectomy and lymphadenectomy. Histopathology reveals intrahepatic cholangiocarcinoma. pT1b, pN2, pM0, R0. Molecular pathology report: Panel (Tumor purity 80%), TMB 1.2 Mut/Mb. Molecular alterations: FGFR2::BICC1 Fusion, TP53 p.E258* (AF 52%).

June 20, 2023: DPD status normal. Initiated adjuvant chemotherapy with Capecitabine.

September 15, 2023: Follow-up CT (chest + abdomen): Multiple new lesions in the remaining liver tissue, highly suggestive of tumor recurrence. New small nodules in the peritoneum, up to 1 cm, likely peritoneal metastasis. FDG-PET shows elevated activity in hepatic and lymph node lesions. Mild right-sided pleural effusion noted, no significant respiratory compromise.

September 17, 2023: Initiated Therapy with Gemzar/Cisplatin + Durvalumab.

September - December 2023: 6 cycles Gemzar/Cisplatin + Durvalumab.

January 5, 2024: Follow-up MRI scan abdomen/liver: progressive disease (PD) with growth of all liver lesions and increased involvement of adjacent hepatic structures. The peritoneal nodules showed slight growth. Moderate ascites. No evidence of direct vascular invasion, but the tumor's close relationship with the hepatic artery and portal vein concerns potential future involvement. The liver parenchyma shows signs of chronic liver disease, possibly secondary to ongoing cholestasis and tumor-related liver dysfunction.

MRI of the brain was conducted concurrently, revealing no evidence of metastatic disease. Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities, consistent with chronic microvascular ischemic changes.

January - March 2024: Second line chemotherapy with FOLFOX.

March 16, 2024: Progressive disease (PD) with significant growth of all liver lesions. The largest lesion in segment IVb has increased to 7.5 cm in diameter, with invasion into the adjacent hepatic structures. The peritoneal nodules have shown further growth, with the largest nodule now measuring 2.5 cm. Ascites: Moderate to severe ascites is present, with a noticeable increase compared to the previous scan. Vascular Involvement: No direct vascular invasion detected yet, but the lesions now encase the hepatic artery and portal vein, raising significant concerns for potential imminent involvement. Liver Parenchyma: The liver parenchyma shows worsening signs of chronic liver disease, likely secondary to ongoing cholestasis and tumor-related liver dysfunction. Evidence of hepatic decompensation is apparent, with diffuse nodularity and fibrosis indicative of cirrhosis.

Additional Findings: Splenomegaly, consistent with portal hypertension.

January 10, 2024:
Patient presented with severe chest pain.
Diagnosed with an acute myocardial infarction.
Underwent emergency coronary angiography, revealing 90%
Occlusion in the LAD and 70% occlusion in the RCA.
Two DES stents placed. Started on aspirin, clopidogrel, atorvastatin, metoprolol,
and lisinopril.

January 20, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

January 21, 2024: Patient in good shape, routine lab results within normal ranges. Willing to participate in potential trials.

===== Patient 8.1.2 =====

Name: Müller, David
Born: 22.03.1970
Address: Hauptstraße 1, Heidelberg, Germany

Overview of Tumor Diagnosis and Therapy
Tumor Diagnosis
Diagnosis: UICC Stage IV FGFR2 mutant intrahepatic cholangiocarcinoma, peritoneal carcinomatosis
Initial Detection: March 5 2022, following symptoms of jaundice and abdominal pain
Molecular Profile:  Panel (Tumor purity 80%), TMB 1.2 Mut/Mb. Molecular alterations: FGFR2::BICC1 Fusion, TP53 p.E258* (AF 52%).

Therapy Overview
Initial Treatment:

Right hemihepatectomy with additional lymphadenectomy June 10, 2023. Histopathology: iCCA, T1b, N1, R0 resection.
Adjuvant chemotherapy: Began June 20, 2023, with Capecitabine. Follow-up CT September 2023 shows multiple new liver lesions and peritoneal metastasis.

Subsequent Treatment:

September - December 2023: 6 cycles Gemzar/Cisplatin + Durvalumab.
January - March 2024: Second line chemotherapy with FOLFOX.

Current Status: ECOG 1

Comorbidities
Hypothyroidism

Hepatitis C

Medication

Levothyroxine 75µg 1-0-0

Sofosbuvir 400 mg, once daily Velpatasvir 100 mg, once daily

Chronological Medical Findings:
February 1, 2023: Complaint of jaundice and abdominal pain. Ultrasound revealed a mass in the liver. Weight loss of -15kg/5 months.

March 5, 2023: MRI of the abdomen: Significant mass measuring approximately 5.5 cm in the right hepatic lobe, consistent with intrahepatic cholangiocarcinoma. Lesion with irregular borders and heterogeneous enhancement patterns. Evidence of bile duct dilation proximal to the mass, suggestive of obstructive cholestasis. Additionally, several enlarged lymph nodes noted in the perihepatic region, displaying increased uptake on FDG-PET, suggestive of potential metastasis. No vascular invasion observed, but the proximity of the mass to the right portal vein concerning for possible future involvement. No signs of distant metastasis present in the visualized organs.

June 10, 2023: Right hemihepatectomy and lymphadenectomy. Histopathology reveals intrahepatic cholangiocarcinoma. pT1b, pN2, pM0, R0. Molecular pathology report: Panel (Tumor purity 80%), TMB 1.2 Mut/Mb. Molecular alterations: FGFR2::BICC1 Fusion, TP53 p.E258* (AF 52%).

June 20, 2023: DPD status normal. Initiated adjuvant chemotherapy with Capecitabine.

September 15, 2023: Follow-up CT (chest + abdomen): Multiple new lesions in the remaining liver tissue, highly suggestive of tumor recurrence. New small nodules in the peritoneum, up to 1 cm, likely peritoneal metastasis. FDG-PET shows elevated activity in hepatic and lymph node lesions. Mild right-sided pleural effusion noted, no significant respiratory compromise.

September 17, 2023: Initiated Therapy with Gemzar/Cisplatin + Durvalumab.

September - December 2023: 6 cycles Gemzar/Cisplatin + Durvalumab.

January 5, 2024: Follow-up MRI scan abdomen/liver: progressive disease (PD) with growth of all liver lesions and increased involvement of adjacent hepatic structures. The peritoneal nodules showed slight growth. Moderate ascites. No evidence of direct vascular invasion, but the tumor's close relationship with the hepatic artery and portal vein concerns potential future involvement. The liver parenchyma shows signs of chronic liver disease, possibly secondary to ongoing cholestasis and tumor-related liver dysfunction.

MRI of the brain was conducted concurrently, revealing no evidence of metastatic disease. Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities, consistent with chronic microvascular ischemic changes.

January - March 2024: Second line chemotherapy with FOLFOX.

March 16, 2024: Progressive disease (PD) with significant growth of all liver lesions. The largest lesion in segment IVb has increased to 7.5 cm in diameter, with invasion into the adjacent hepatic structures. The peritoneal nodules have shown further growth, with the largest nodule now measuring 2.5 cm. Ascites: Moderate to severe ascites is present, with a noticeable increase compared to the previous scan. Vascular Involvement: No direct vascular invasion detected yet, but the lesions now encase the hepatic artery and portal vein, raising significant concerns for potential imminent involvement. Liver Parenchyma: The liver parenchyma shows worsening signs of chronic liver disease, likely secondary to ongoing cholestasis and tumor-related liver dysfunction. Evidence of hepatic decompensation is apparent, with diffuse nodularity and fibrosis indicative of cirrhosis.

Additional Findings: Splenomegaly, consistent with portal hypertension.

January 20, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

January 21, 2024: Patient progressively in bad shape, stays in bed almost all day, routine lab results within normal ranges. Willing to participate in potential trials.

===== Patient 9.1 =====

Patient Information

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%), p.H1047R (AF 30%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel plus Trastuzumab. Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin and paclitaxel initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 1

Comorbidities

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Amlodipine 10 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal liver and renal function. The patient maintained an ECOG performance status of 1.

===== Patient 9.1.1 =====

Patient Information

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%), p.H1047R (AF 30%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel plus Trastuzumab. Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin and paclitaxel initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 2

Comorbidities

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

HFrEF NYHA II

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Candesartan 12 mg 1-0-0

Metoprolol 47,5 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal liver and moderately reduced renal function (eGFR 65 ml/min/1.73m²). The patient maintained an ECOG performance status of 2.

===== Patient 9.1.2 =====

Patient Information

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%), p.H1047R (AF 30%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel plus Trastuzumab. Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin and paclitaxel initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 3

Comorbidities

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Candesartan 12 mg 1-0-0

Metoprolol 47,5 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Status assessment before possible study enrollment.
Patient shows reduced overall health, ECOG performance status now 3.
Lab results show liver and kidney injury: Total bilirubin 4.5 mg/dl, AST 230 U/L,
ALT 180 U/L, AP 320 U/L, GGT 30 U/L, Albumin 2.3 g/dl.
Creatinine 3.2 mg/dl, eGFR 20.6 ml/min/m².

===== Patient 9.1.3 =====

Patient Information

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%), p.H1047R (AF 30%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel plus Trastuzumab. Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin and paclitaxel initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 3

Comorbidities

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

UICC Stage III melanoma, diagnosed 10/2021
(currently on Nivolumab maintenance)

Medication

Candesartan 12 mg 1-0-0

Metoprolol 47,5 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Status assessment before possible study enrollment.
Patient shows reduced overall health, ECOG performance status now 3.
Lab results show liver and kidney injury: Total bilirubin 4.5 mg/dl, AST 230 U/L,
ALT 180 U/L, AP 320 U/L, GGT 30 U/L, Albumin 2.3 g/dl.
Creatinine 3.2 mg/dl, eGFR 20.6 ml/min/m².

===== Patient 9.2 =====

Patient Information

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel (70 mg/m²) plus Trastuzumab (8 mg/kg). Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin (6 mg/m²/min) and paclitaxel (200 mg/m² q3week) initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 1

Comorbidities

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Amlodipine 10 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal liver and renal function. The patient maintained an ECOG performance status of 1.

===== Patient 9.2.1 =====

Patient Information

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel (70 mg/m²) plus Trastuzumab (8 mg/kg). Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin (6 mg/m²/min) and paclitaxel (200 mg/m² q3week) initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 1

Comorbidities

HIV (current viral load undetectable)

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Amlodipine 10 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Bictegravir/Emtricitabine/Tenofovir alafenamide 50mg/200mg/25mg 1-0-0

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal liver and renal function. The patient maintained an ECOG performance status of 1.

===== Patient 9.2.2 =====

Patient Information

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel (70 mg/m²) plus Trastuzumab (8 mg/kg). Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin (6 mg/m²/min) and paclitaxel (200 mg/m² q3week) initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 1

Comorbidities

Former smoker 30 py

Hypertension Stage 1

HFrEF NYHA II

Type 2 Diabetes Mellitus

Generalized Epilepsy

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Candesartan 12 mg 1-0-0 Metoprolol 47,5 mg 1-0-0 Valproic acid 500mg 2-0-2

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal liver and renal function. The patient maintained an ECOG performance status of 1.

===== Patient 9.2.3 =====

Patient Information

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel (70 mg/m²) plus Trastuzumab (8 mg/kg). Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin (6 mg/m²/min) and paclitaxel (200 mg/m² q3week) initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary, hepatic and brain metastasis.

ECOG 1

Comorbidities

Alcohol dependence

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Amlodipine 10 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 5, 2024: MRI scan of the brain revealed multiple metastases,
specifically two lesions in the left hemisphere:
one in the left frontal lobe and one in the left occipital lobe.
Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities consistent with chronic microvascular ischemic changes.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal liver and renal function. The patient maintained an ECOG performance status of 1.

===== Patient 9.3 =====

Patient Information 

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel plus Trastuzumab. Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin and paclitaxel initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 1

Comorbidities

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Amlodipine 10 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal liver and renal function. The patient maintained an ECOG performance status of 1.

===== Patient 9.3.1 =====

Patient Information 

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel plus Trastuzumab. Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin and paclitaxel initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 2

Comorbidities

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

CKD KDIGO G4

Medication

Amlodipine 10 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal organ function except for known reduced kidney function: eGFR 21.56 ml/min/1.73m²,
Creatinine 3.0 mg/dl.
Current ECOG performance status 2.

===== Patient 9.3.2 =====

Patient Information 

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel plus Trastuzumab. Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin and paclitaxel initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary and hepatic metastasis.

ECOG 1

Active P. jirovecii pneumonia

Comorbidities

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Sulfamethoxazole/Trimethoprim 400mg/80mg 5–5-5-5

Amlodipine 10 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal liver and renal function. The patient maintained an ECOG performance status of 1.

===== Patient 9.3.3 =====

Patient Information 

Name: Mueller, Max

Born: 25.03.1945

Address: 456 Oak Street, Hamburg, Germany

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: Stage IV salivary duct carcinoma

Initial Detection: June 10, 2023, following symptoms of persistent facial swelling and pain

Biopsy Date: July 5, 2023

Molecular Profile: Tumor Mutational Burden (TMB) of 10.5 Mut/Mb, HRAS p.Q61R (AF 44%), PIK3CA p.E545K (AF 39%). HER2 FISH positive.

Therapy Overview

Initial Treatment:

Chemotherapy: Initiated on August 1, 2023, with Docetaxel plus Trastuzumab. Partial response noted after three months.

Subsequent Treatment: Second-line chemotherapy with carboplatin and paclitaxel initiated on December 1, 2023, due to disease progression.

Current Status: Progressive disease with lymphatic, pulmonary, hepatic and brain metastasis.

ECOG 1

Comorbidities

Former smoker 30 py

Hypertension Stage 1

Type 2 Diabetes Mellitus

Hyperlipidemia

Benign Prostatic Hyperplasia (BPH)

Medication

Amlodipine 10 mg 1-0-0

Metformin 1000 mg 1-0-1

Empagliflozin 10mg 1-0-0

Atorvastatin 40 mg 0-0-0-1

Omeprazole 20 mg 1-0-0

Tamsulosin 0.4 mg 1-0-0

Fentanyl TTS 25 mcg every 3 days

Fentanyl s.l. 100 mcg as needed up to 4 times a day

Ibuprofen 600 1-1-1

Chronological Medical Findings:

June 10, 2023: Patient presented with persistent facial swelling and pain. A CT scan of the head and neck revealed a mass in the left parotid gland measuring approximately 5 cm with extensive local invasion into the surrounding soft tissues and suspected involvement of multiple regional lymph nodes in levels II and III

June 12, 2023: Staging CT-scan (chest and abdomen). Multiple nodular lesions are identified in the right lung, consistent with metastatic disease. The largest lesion is located in the right lower lobe, measuring approximately 2.5 cm in diameter. Additional smaller nodules are noted in the right upper and middle lobes, with the largest of these measuring up to 1.2 cm. No signs of metastatic involvement in the abdomen.

June 15, 2023: Brain MRI. No signs of brain metastasis.

July 5, 2023: Ultrasound-guided biopsy confirmed salivary duct carcinoma with high TMB and specific genetic mutations (HRAS p.Q61R, PIK3CA p.E545K). FISH positive for HER2 amplification.

July 12, 2023: Started on Docetaxel and Trastuzumab.

October 15, 2023: Follow-Up imaging: CT scan of the head and neck showed a reduction in tumor size to approximately 3.5 cm. Regional lymph nodes remained enlarged but showed decreased metabolic activity on PET scan. All pulmonary lesions show minimal reduction in size compared to previous scan. No new metastatic lesions.

January 1, 2024: Follow-up CT scan (neck, chest and abdomen) indicated disease progression. Primary tumor remains stable in size, as well as known lymph node metastases. Pulmonary metastases all show tumor growth with the largest lesion in the right lower lobe now measuring 2.8 cm in diameter. Multiple, previously unknown hypodense lesion within the left liver lobe, compatible with metastatic disease. PET scan shows high metabolic activity.

January 4, 2024: MRI scan of the brain revealed multiple metastases,
specifically two lesions in the right hemisphere:
one in the right frontal lobe and one in the right parietal lobe.
Incidental findings included mild age-related cerebral atrophy and scattered white matter hyperintensities consistent with chronic microvascular ischemic changes.

January 9, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

March 15, 2024: Routine Labs: Comprehensive blood work indicated normal liver and renal function. The patient maintained an ECOG performance status of 1.

===== Patient 10.1 =====

Name: Miller, Jane
Born: 25.07.1965
Address: Main Street 78, Potsdam

Overview of Tumor Diagnosis and Therapy
Tumor Diagnosis
Diagnosis: UICC Stage IV EGFR mutated non-small cell lung cancer (NSCLC)
Initial Detection: January 10, 2023, following symptoms of persistent cough and chest pain
Biopsy Date: February 5, 2023, adenocarcinoma of the lung
Molecular Profile: Panel (tumor purity 60%). EGFR p.E746_A750del (AF 50%), EGFR T790M, EGFR p.C797S (AF 29%), STK11 p.C210* (AF 39%).

Therapy Overview
Initial Treatment:
Targeted Therapy: Began March 1, 2023, with Osimertinib  (T790M). Partial response noted after initial therapy cycle completed by June 15, 2023. Continued therapy until November 2021 (progressive disease).

Subsequent Treatment:
Further treatment with Pembrolizumab in combination with Paclitaxel/Carboplatin/ Bevacizumab and Atezolizumab initiated on December 1, 2023. Staging CT shows disease progression after 6 months.

Current Status: ECOG 1

Comorbidities
Current smoker: 35 py

Hypertension Stage 1
Hyperlipidemia: Managed with Simvastatin 20 mg daily
COPD GOLD 2

Medication

Losartan 50mg 1-0-0

Simvastatin 20mg daily 0-0-0-1

Albuterol (inhaler) on demand

Tiotropium (inhaler) on demand

Chronological Medical Findings:
January 2023: Complaints of persistent cough and bloody sputum. Weight loss of -10kg / 5 months. Chest X-ray revealed a mass in the right lung.

January 10, 2023: Comprehensive CT scan (chest and abdomen): Solid, spiculated mass in the right upper lobe of the lung measuring approximately 3.8 cm. Additionally, three small hypoattenuating hepatic lesions noted, to be considered as metastases. Enlarged hilar and subcarinal lymph nodes. Right adrenal gland slightly enlarged, warranting further investigation for metastatic involvement. No evidence of pleural effusion or significant vascular invasion was present. Additional notes: Minor atelectasis in the left lower lobe and mild emphysematous changes in both lungs, consistent with the patient’s history of chronic obstructive pulmonary disease (COPD). The abdominal organs, aside from the hepatic lesions and possible adrenal metastasis, appeared unremarkable.

February 5, 2023: Biopsy and molecular testing confirmed adenocarcinoma with EGFR T790M mutation. Material sent for further panel testing. Initiated Osimertinib therapy on March 1, 2021. Patient signed consent. Patient in clinical good condition.

Feb.-June 2023: Antineoplastic targeted therapy with Osimertinib.

June 15, 2023: Follow-up CT scan (chest and abdomen), PET CT scan: Partial response (PR) to treatment. The primary lung mass in the right upper lobe decreased in size, now measuring approximately 3 cm in diameter, down from 3.8 cm. The three previously noted hypoattenuating hepatic lesions have also shown slight reduction in size and decreased metabolic activity, suggesting a positive response to systemic therapy. No new metastatic lesions detected in the liver or other abdominal organs. The previously enlarged hilar and subcarinal lymph nodes have reduced in size, indicating a favorable response to treatment. The right adrenal gland remains slightly enlarged but stable, with no significant change noted, and it continues to show no signs of active disease. Overall: PR.

July 1, 2023: Continuation of Osimertinib therapy

October 3, 2023: CT scan Chest/Abd.: PD. The primary lung mass in the right upper lobe has increased in size, now measuring approximately 4.5 cm in diameter (prev 3,0 cm). The previously noted hypoattenuating hepatic lesions have also shown slight growth. Additional new metastasis in S7. Small pleural effusion on the right side, minor atelectasis in the left lower lobe has slightly worsened. Hilar and subcarinal lymph nodes drastically enlarged in size. Right adrenal gland with second metastasis. No new metastatic lesions were detected in the liver or other abdominal organs.

December 1, 2023: Begin Paclitaxel/Carboplatin/Bevacizumab and Atezolizumab. Received written consent from the patient, ECOG 1.

May 10, 2024: CT Lung/Abdomen: Progressive Disease. Primary lung mass in the right upper lobe has increased in size, now measuring approximately 4.5 cm in diameter, up from 3 cm. The previously noted hypoattenuating hepatic lesions have also shown slight growth. Small pleural effusion on the right side. Minor atelectasis in the left lower lobe slightly worsened, likely due to the progressive nature of the disease and the presence of pleural effusion. The hilar and subcarinal lymph nodes, prev. reduced in size, now slightly enlarged again. Right adrenal gland remains slightly enlarged and stable with no significant change in size. No new metastatic lesions were detected in the liver or other abdominal organs.

Summary:

Primary Lung Mass: Increased in size to 4.5 cm.

Hepatic Lesions: Slight growth and increased metabolic activity.

Lymph Nodes: Slightly re-enlarged hilar and subcarinal nodes.

Pleural Effusion: Small right-sided pleural effusion noted.

Atelectasis: Slight worsening of minor atelectasis in the left lower lobe.

Adrenal Gland: Remains slightly enlarged; increased metabolic activity.

Overall Assessment: Disease progression (PD).

May 15, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

May 18, 2024: Detailed assessment of health status. ECOG performance 1. All routine labs, including liver and renal function tests, within normal limits.

===== Patient 10.1.1 =====

Name: Miller, Jane
Born: 25.07.1965
Address: Main Street 78, Potsdam

Overview of Tumor Diagnosis and Therapy
Tumor Diagnosis
Diagnosis: UICC Stage IV EGFR mutated non-small cell lung cancer (NSCLC)
Initial Detection: January 10, 2023, following symptoms of persistent cough and chest pain
Biopsy Date: February 5, 2023, adenocarcinoma of the lung
Molecular Profile: Panel (tumor purity 60%). EGFR p.E746_A750del (AF 50%), EGFR T790M, EGFR p.C797S (AF 29%), STK11 p.C210* (AF 39%).

Therapy Overview
Initial Treatment:
Targeted Therapy: Began March 1, 2023, with Osimertinib  (T790M). Partial response noted after initial therapy cycle completed by June 15, 2023. Continued therapy until November 2021 (progressive disease).

Subsequent Treatment:
Further treatment with Pembrolizumab in combination with Paclitaxel/Carboplatin/ Bevacizumab and Atezolizumab initiated on December 1, 2023. Staging CT shows disease progression after 6 months.

Current Status:
ECOG 1

Comorbidities
Current smoker: 35 py

Hypertension Stage 1
Hyperlipidemia: Managed with Simvastatin 20 mg daily
COPD GOLD 2

Medication

Losartan 50mg 1-0-0

Simvastatin 20mg daily 0-0-0-1

Albuterol (inhaler) on demand

Tiotropium (inhaler) on demand

Chronological Medical Findings:
January 2023: Complaints of persistent cough and bloody sputum. Weight loss of -10kg / 5 months. Chest X-ray revealed a mass in the right lung.

January 10, 2023: Comprehensive CT scan (chest and abdomen): Solid, spiculated mass in the right upper lobe of the lung measuring approximately 3.8 cm. Additionally, three small hypoattenuating hepatic lesions noted, to be considered as metastases. Enlarged hilar and subcarinal lymph nodes. Right adrenal gland slightly enlarged, warranting further investigation for metastatic involvement. No evidence of pleural effusion or significant vascular invasion was present. Additional notes: Minor atelectasis in the left lower lobe and mild emphysematous changes in both lungs, consistent with the patient’s history of chronic obstructive pulmonary disease (COPD). The abdominal organs, aside from the hepatic lesions and possible adrenal metastasis, appeared unremarkable.

February 5, 2023: Biopsy and molecular testing confirmed adenocarcinoma with EGFR T790M mutation. Material sent for further panel testing. Initiated Osimertinib therapy on March 1, 2021. Patient signed consent. Patient in clinical good condition.

Feb.-June 2023: Antineoplastic targeted therapy with Osimertinib.

June 15, 2023: Follow-up CT scan (chest and abdomen), PET CT scan: Partial response (PR) to treatment. The primary lung mass in the right upper lobe decreased in size, now measuring approximately 3 cm in diameter, down from 3.8 cm. The three previously noted hypoattenuating hepatic lesions have also shown slight reduction in size and decreased metabolic activity, suggesting a positive response to systemic therapy. No new metastatic lesions detected in the liver or other abdominal organs. The previously enlarged hilar and subcarinal lymph nodes have reduced in size, indicating a favorable response to treatment. The right adrenal gland remains slightly enlarged but stable, with no significant change noted, and it continues to show no signs of active disease. Overall: PR.

July 1, 2023: Continuation of Osimertinib therapy

October 3, 2023: CT scan Chest/Abd.: PD. The primary lung mass in the right upper lobe has increased in size, now measuring approximately 4.5 cm in diameter (prev 3,0 cm). The previously noted hypoattenuating hepatic lesions have also shown slight growth. Additional new metastasis in S7. Small pleural effusion on the right side, minor atelectasis in the left lower lobe has slightly worsened. Hilar and subcarinal lymph nodes drastically enlarged in size. Right adrenal gland with second metastasis. No new metastatic lesions were detected in the liver or other abdominal organs.

December 1, 2023: Begin Paclitaxel/Carboplatin/Bevacizumab and Atezolizumab. Received written consent from the patient, ECOG 1.

May 8, 2024: Stopped platin because of severe neuropathy (CTCAE III)

May 10, 2024: CT Lung/Abdomen: Progressive Disease. Primary lung mass in the right upper lobe has increased in size, now measuring approximately 4.5 cm in diameter, up from 3 cm. The previously noted hypoattenuating hepatic lesions have also shown slight growth. Small pleural effusion on the right side. Minor atelectasis in the left lower lobe slightly worsened, likely due to the progressive nature of the disease and the presence of pleural effusion. The hilar and subcarinal lymph nodes, prev. reduced in size, now slightly enlarged again. Right adrenal gland remains slightly enlarged and stable with no significant change in size. No new metastatic lesions were detected in the liver or other abdominal organs.

Summary:

Primary Lung Mass: Increased in size to 4.5 cm.

Hepatic Lesions: Slight growth and increased metabolic activity.

Lymph Nodes: Slightly re-enlarged hilar and subcarinal nodes.

Pleural Effusion: Small right-sided pleural effusion noted.

Atelectasis: Slight worsening of minor atelectasis in the left lower lobe.

Adrenal Gland: Remains slightly enlarged; increased metabolic activity.

Overall Assessment: Disease progression (PD).

May 15, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

May 18, 2024: Detailed assessment of health status. ECOG performance 1. All routine labs, including liver and renal function tests, within normal limits.

May 20, 2024: Presentation with shortness of breath via emergeny.
CT scan with multiple infiltrates.
CRP elevated at 190. Started on Meropenem. Admitted for inpatient care.

===== Patient 10.1.2 =====

Name: Miller, Jane
Born: 25.07.1965
Address: Main Street 78, Potsdam

Overview of Tumor Diagnosis and Therapy
Tumor Diagnosis
Diagnosis: UICC Stage IV EGFR mutated non-small cell lung cancer (NSCLC)
Initial Detection: January 10, 2023, following symptoms of persistent cough and chest pain
Biopsy Date: February 5, 2023, adenocarcinoma of the lung
Molecular Profile: Panel (tumor purity 60%). EGFR p.E746_A750del (AF 50%), EGFR T790M, EGFR p.C797S (AF 29%), STK11 p.C210* (AF 39%).

Therapy Overview
Initial Treatment:
Targeted Therapy: Began March 1, 2023, with Osimertinib  (T790M). Partial response noted after initial therapy cycle completed by June 15, 2023. Continued therapy until November 2021 (progressive disease).

Subsequent Treatment:
Further treatment with Pembrolizumab in combination with Paclitaxel/Carboplatin/ Bevacizumab and Atezolizumab initiated on December 1, 2023. Staging CT shows disease progression after 6 months.

Current Status:
ECOG 1

Comorbidities
Current smoker: 35 py

Hypertension Stage 1
Hyperlipidemia: Managed with Simvastatin 20 mg daily
COPD GOLD 2

Medication

Losartan 50mg 1-0-0

Simvastatin 20mg daily 0-0-0-1

Albuterol (inhaler) on demand

Tiotropium (inhaler) on demand

Chronological Medical Findings:
January 2023: Complaints of persistent cough and bloody sputum. Weight loss of -10kg / 5 months. Chest X-ray revealed a mass in the right lung.

January 10, 2023: Comprehensive CT scan (chest and abdomen): Solid, spiculated mass in the right upper lobe of the lung measuring approximately 3.8 cm. Additionally, three small hypoattenuating hepatic lesions noted, to be considered as metastases. Enlarged hilar and subcarinal lymph nodes. Right adrenal gland slightly enlarged, warranting further investigation for metastatic involvement. No evidence of pleural effusion or significant vascular invasion was present. Additional notes: Minor atelectasis in the left lower lobe and mild emphysematous changes in both lungs, consistent with the patient’s history of chronic obstructive pulmonary disease (COPD). The abdominal organs, aside from the hepatic lesions and possible adrenal metastasis, appeared unremarkable.

February 5, 2023: Biopsy and molecular testing confirmed adenocarcinoma with EGFR T790M mutation. Material sent for further panel testing. Initiated Osimertinib therapy on March 1, 2021. Patient signed consent. Patient in clinical good condition.

Feb.-June 2023: Antineoplastic targeted therapy with Osimertinib.

June 15, 2023: Follow-up CT scan (chest and abdomen), PET CT scan: Partial response (PR) to treatment. The primary lung mass in the right upper lobe decreased in size, now measuring approximately 3 cm in diameter, down from 3.8 cm. The three previously noted hypoattenuating hepatic lesions have also shown slight reduction in size and decreased metabolic activity, suggesting a positive response to systemic therapy. No new metastatic lesions detected in the liver or other abdominal organs. The previously enlarged hilar and subcarinal lymph nodes have reduced in size, indicating a favorable response to treatment. The right adrenal gland remains slightly enlarged but stable, with no significant change noted, and it continues to show no signs of active disease. Overall: PR.

July 1, 2023: Continuation of Osimertinib therapy

October 3, 2023: CT scan Chest/Abd.: PD. The primary lung mass in the right upper lobe has increased in size, now measuring approximately 4.5 cm in diameter (prev 3,0 cm). The previously noted hypoattenuating hepatic lesions have also shown slight growth. Additional new metastasis in S7. Small pleural effusion on the right side, minor atelectasis in the left lower lobe has slightly worsened. Hilar and subcarinal lymph nodes drastically enlarged in size. Right adrenal gland with second metastasis. No new metastatic lesions were detected in the liver or other abdominal organs.

December 1, 2023: Begin Paclitaxel/Carboplatin/Bevacizumab and Atezolizumab. Received written consent from the patient, ECOG 1.

May 10, 2024: CT Lung/Abdomen: Progressive Disease. Primary lung mass in the right upper lobe has increased in size, now measuring approximately 4.5 cm in diameter, up from 3 cm. The previously noted hypoattenuating hepatic lesions have also shown slight growth. Small pleural effusion on the right side. Minor atelectasis in the left lower lobe slightly worsened, likely due to the progressive nature of the disease and the presence of pleural effusion. The hilar and subcarinal lymph nodes, prev. reduced in size, now slightly enlarged again. Right adrenal gland remains slightly enlarged and stable with no significant change in size. No new metastatic lesions were detected in the liver or other abdominal organs.

Summary:

Primary Lung Mass: Increased in size to 4.5 cm.

Hepatic Lesions: Slight growth and increased metabolic activity.

Lymph Nodes: Slightly re-enlarged hilar and subcarinal nodes.

Pleural Effusion: Small right-sided pleural effusion noted.

Atelectasis: Slight worsening of minor atelectasis in the left lower lobe.

Adrenal Gland: Remains slightly enlarged; increased metabolic activity.

Overall Assessment: Disease progression (PD).

May 11, 2024: Seizures, CT scan: 3 metastases in the brain:
1x2.5 cm lesion in the left frontal lobe.
A 1.8 cm lesion in the right parietal lobe. A 1.2 cm lesion in the cerebellum.
Initiated Prednisone. Begin with Keppra.
Consultation with the radiation oncology team, recommended
whole-brain radiotherapy (30 Gy in 10 fractions).
Surgical resection deemed not possible due to location of metasases.

May 15, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

May 18, 2024: Detailed assessment of health status. ECOG performance 1. All routine labs, including liver and renal function tests, within normal limits.

===== Patient 10.1.3 =====

Name: Miller, Jane
Born: 25.07.1965
Address: Main Street 78, Potsdam

Overview of Tumor Diagnosis and Therapy
Tumor Diagnosis
Diagnosis: UICC Stage IV EGFR mutated non-small cell lung cancer (NSCLC)
Initial Detection: January 10, 2023, following symptoms of persistent cough and chest pain
Biopsy Date: February 5, 2023, adenocarcinoma of the lung
Molecular Profile: Panel (tumor purity 60%). EGFR p.E746_A750del (AF 50%), EGFR T790M, EGFR p.C797S (AF 29%), STK11 p.C210* (AF 39%).

Therapy Overview
Initial Treatment:
Targeted Therapy: Began March 1, 2023, with Osimertinib  (T790M). Partial response noted after initial therapy cycle completed by June 15, 2023. Continued therapy until November 2021 (progressive disease).

Subsequent Treatment:
Further treatment with Pembrolizumab in combination with Paclitaxel/Carboplatin/ Bevacizumab and Atezolizumab initiated on December 1, 2023. Staging CT shows disease progression after 6 months.

Current Status:
ECOG 1

Comorbidities
Current smoker: 35 py

Hypertension Stage 1
Hyperlipidemia: Managed with Simvastatin 20 mg daily
COPD GOLD 2 Diabetes Mellitus (II)  Diabetic Retinopathy

Medication

Losartan 50mg 1-0-0

Simvastatin 20mg daily 0-0-0-1

Metformin  (800 mg 1-0-1)

Albuterol (inhaler) on demand

Tiotropium (inhaler) on demand

Lucentis

Chronological Medical Findings:
January 2023: Complaints of persistent cough and bloody sputum. Weight loss of -10kg / 5 months. Chest X-ray revealed a mass in the right lung.

January 10, 2023: Comprehensive CT scan (chest and abdomen): Solid, spiculated mass in the right upper lobe of the lung measuring approximately 3.8 cm. Additionally, three small hypoattenuating hepatic lesions noted, to be considered as metastases. Enlarged hilar and subcarinal lymph nodes. Right adrenal gland slightly enlarged, warranting further investigation for metastatic involvement. No evidence of pleural effusion or significant vascular invasion was present. Additional notes: Minor atelectasis in the left lower lobe and mild emphysematous changes in both lungs, consistent with the patient’s history of chronic obstructive pulmonary disease (COPD). The abdominal organs, aside from the hepatic lesions and possible adrenal metastasis, appeared unremarkable.

February 5, 2023: Biopsy and molecular testing confirmed adenocarcinoma with EGFR T790M mutation. Material sent for further panel testing. Initiated Osimertinib therapy on March 1, 2021. Patient signed consent. Patient in clinical good condition.

Feb.-June 2023: Antineoplastic targeted therapy with Osimertinib.

June 15, 2023: Follow-up CT scan (chest and abdomen), PET CT scan: Partial response (PR) to treatment. The primary lung mass in the right upper lobe decreased in size, now measuring approximately 3 cm in diameter, down from 3.8 cm. The three previously noted hypoattenuating hepatic lesions have also shown slight reduction in size and decreased metabolic activity, suggesting a positive response to systemic therapy. No new metastatic lesions detected in the liver or other abdominal organs. The previously enlarged hilar and subcarinal lymph nodes have reduced in size, indicating a favorable response to treatment. The right adrenal gland remains slightly enlarged but stable, with no significant change noted, and it continues to show no signs of active disease. Overall: PR.

July 1, 2023: Continuation of Osimertinib therapy

October 3, 2023: CT scan Chest/Abd.: PD. The primary lung mass in the right upper lobe has increased in size, now measuring approximately 4.5 cm in diameter (prev 3,0 cm). The previously noted hypoattenuating hepatic lesions have also shown slight growth. Additional new metastasis in S7. Small pleural effusion on the right side, minor atelectasis in the left lower lobe has slightly worsened. Hilar and subcarinal lymph nodes drastically enlarged in size. Right adrenal gland with second metastasis. No new metastatic lesions were detected in the liver or other abdominal organs.

December 1, 2023: Begin Paclitaxel/Carboplatin/Bevacizumab and Atezolizumab. Received written consent from the patient, ECOG 1.

May 10, 2024: CT Lung/Abdomen: Progressive Disease. Primary lung mass in the right upper lobe has increased in size, now measuring approximately 4.5 cm in diameter, up from 3 cm. The previously noted hypoattenuating hepatic lesions have also shown slight growth. Small pleural effusion on the right side. Minor atelectasis in the left lower lobe slightly worsened, likely due to the progressive nature of the disease and the presence of pleural effusion. The hilar and subcarinal lymph nodes, prev. reduced in size, now slightly enlarged again. Right adrenal gland remains slightly enlarged and stable with no significant change in size. No new metastatic lesions were detected in the liver or other abdominal organs.

Summary:

Primary Lung Mass: Increased in size to 4.5 cm.

Hepatic Lesions: Slight growth and increased metabolic activity.

Lymph Nodes: Slightly re-enlarged hilar and subcarinal nodes.

Pleural Effusion: Small right-sided pleural effusion noted.

Atelectasis: Slight worsening of minor atelectasis in the left lower lobe.

Adrenal Gland: Remains slightly enlarged; increased metabolic activity.

Overall Assessment: Disease progression (PD).

May 15, 2024: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

May 18, 2024: Detailed assessment of health status.
Patient progressively in worse conditions, currently ECOG performance 2.
All routine labs, including liver and renal function tests, within normal limits.

===== Patient 11.1 =====

Patient Information

Name: Smith, Anna

Born: 10.03.1980

Address: Another Avenue 89, Augsburg

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IV well-differentiated, non-functioning neuroendocrine tumor of the pancreas

Initial Detection: June 5, 2021, following symptoms of abdominal pain and weight loss

Biopsy Date: July 1, 2021, well-differentiated neuroendocrine tumor of the pancreas

Molecular Profile: High Tumor Mutational Burden (TMB-H, >=10 mut/Mb, F1CDx assay)

Therapy Overview

Initial Treatment:

Chemotherapy: Began July 20, 2021, with Capecitabine and Temozolomide regimen. Partial response noted after initial chemotherapy cycle completed by October 10, 2021. Continued therapy until January 2022 (progressive disease).

Subsequent Treatment:

Further chemotherapy with Everolimus initiated on February 1, 2022. Staging CT shows disease progression after 6 months.

Current Status: ECOG 1

Comorbidities

Hypertension Stage 2

History of appendectomy 2001

Medication

Ramipril 10mg 1-0-0

Amlodipin 5mg 1-0-0

Hydrochlorothiazide 12.5mg 1-0-0

Chronological Medical Findings:

May 10, 2021: Complained of abdominal pain and weight loss. Abdominal ultrasound revealed a mass in the pancreas. Referred to oncologist. No symptoms attributable to carcinoid syndrome.

June 5, 2021: CT scan of the abdomen and pelvis: Revealed a well-defined mass in the head of the pancreas measuring approximately 4.5 cm with surrounding lymphadenopathy. No signs of vascular invasion, but multiple small hepatic lesions were identified, indicating metastatic disease. No evidence of bowel obstruction, but slight dilation of the pancreatic duct was observed.

July 1, 2021: Biopsy and molecular testing confirmed a well-differentiated neuroendocrine tumor with a high tumor mutational burden (TMB-H, >=10 mut/Mb, F1CDx assay), Grade 3. Initiated Capecitabine and Temozolomide chemotherapy regimen on July 20, 2021.

October 10, 2021: Follow-up CT scan (chest, abdomen, and pelvis): Partial response to treatment observed, with the primary pancreatic mass reducing to 3.5 cm in diameter. Hepatic lesions showed slight reduction in size and metabolic activity. No new metastatic lesions were detected, but mild ascites persisted.

January 1, 2022: Continued Capecitabine and Temozolomide therapy, with staging scans showing moderate disease progression. Primary mass increased to 4.0 cm, with new peritoneal nodules.

February 1, 2022: Initiated Everolimus therapy due to progression on previous regimen.

August 1, 2022: Follow-up MRI scan (abdomen and pelvis): MRI indicated further disease progression, with the primary tumor enlarging to 4.8 cm and increased involvement of adjacent hepatic structures. Peritoneal nodules showed slight growth, and moderate ascites was present. There was no evidence of bowel obstruction or significant vascular invasion.

November 15, 2022: Tumor board recommends considering clinical trial options due to limited response to standard therapies.

December 1, 2022: Detailed assessment of health status. ECOG performance status 1. All routine labs, including liver and renal function tests, within normal limits.

===== Patient 11.1.1 =====

Patient Information

Name: Smith, Anna

Born: 10.03.1980

Address: Another Avenue 89, Augsburg

Overview of Tumor Diagnosis and Therapy

Tumor Diagnosis

Diagnosis: UICC Stage IV well-differentiated, non-functioning neuroendocrine tumor of the pancreas